Indian Patents
Title of Invention

PHARMACEUTICAL COMPOSITION OF ADAMANTANE DERIVATIVES
Abstract N/A
Full Text FORM 2
THE PATENTS ACT 1970
[39 OF 1970]
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
[See Section 10; rule 13]
"PHARMACEUTICAL COMPOSITION"
ASTRAZENECA AB, a Swedish company, of S-151 85 Sodertalje, Sweden,
The following specification particularly describes the invention and the manner in which it is to be performed:

WO 01/44170

PCT/SE00/02505

1
ADAMANTANE DERIVATIVES
The present invention relates to adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the 5 pharmaceutical compositions, and their use in therapy.
The P2X7 receptor (previously known as P2Z receptor), which is a ligand-gated ion
channel, is present on a variety of cell types, largely those known to be involved in the
inflammatory/irnmune process, specifically, macrophages, mast cells and lymphocytes 10 (T and B). Activation of the P2X7 receptor by extracellular nucleotides, in particular
adenosine triphosphate, leads to the release of interleukin-1 p (IL-1 p) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and L-selectin shedding (lymphocytes). P2X7 receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells), hepatocytes, erythrocytes, is erythroleukaemic cells, monocytes, fibroblasts, bone marrow cells, neurones and renal mesangial cells.
- It would be desirable to make compounds, effective as P2X7 receptor antagonists for
use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies 20 of which the P2X7 receptor may play a role. •
In accordance with the present invention, there is therefore provided a compound of general formula

CO
25 wherein D represents CH2 or CH2GH2, preferably CH2;

WO 01/44170

PCT/SEOO/02505

2
E represents C(0)NH or, preferably, NHC(O);
12 R and R each independently represent hydrogen, halogen (e.g. fluorine, chlorine,
bromine or iodine), amino (NH2), nitro (NO2), CrC6 alkyl or trifluoromethyl, butR
andR may not.hoth simultaneously represent hydrogen;
R represents a group of formula
. (ii);
R represents a CrC6 alkyl group;
X represents an oxygen or sulphur atom or a group NR , SO or S02; 10 R represents hydrogen, or R represents CpCg alkyl or C2-Cg alkenyl, each of which may be optionally substituted by at least'one substituent selected from halogen, hydroxyl, (di)-CrC6-alkylamino, -Y-R6,



15
2, and a 5- or 6-membered heteroaromatic ring comprising from 1 to 4 heteroatoms independent!] selected from nitrogen, oxygen and sulphur which heteroaromatic ring may itself be optionally substituted by at least one substituent selected from halogen, hydroxyl and CrC6 alkyl;
20
Y represents an oxygen or sulphur atom or a group NH, $0 or S02; R represents a group -R Z where R represents a C2-C6 alkyl group and Z represents an -OH, -C02H, -NR8R9, -C(O)NR10RH or -N(R12)C(0)-CrC6 alkyl group, and, in the case where Y represents an oxygen or sulphur atom or a group NH, R additionally represents.hydrogen, Ci~C6 alkyl, C^-Cg alkylcarbonyl, C^C^ alkoxycarbonyl, -C(0)NR14R15, -CH2OC(0)R16, -CH2OC(0)OR17 or -C(0)0CH20R18;
8 9 10 11 12 '
R , R , R , R and R each independently represent a hydrogen atom or a Ci-C6 alkyl
25 group;
R13 represents hydrogen, C3-C8 cycloalkyl, C3-C8 cycloalkylmethyl, or R represents a
CrC6 alkyl group optionally substituted by at least one substituent selected from hydroxyl
andCpCgalkoxy; and

WO 01/44170

PCT/SEOO/02505

3
R14, R15, R16, R17 and R18 each independently represent a CrC6 alkyl group;
with the proviso that when E is C(0)NH, X is O, NH or N(CrC6 alkyl), thenR is Other
than a hydrogen atom or an unsubstituted C ]-C or a pharmaceutically acceptable salt or solvate thereof.
5
In the context of the present specification, unless otherwise indicated, an alkyl substituent or alkyl moiety in a substituent group may be linear or branched. In the present invention, an alkyl group or moiety may contain up to 6 carbon atoms, examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl and n-hexyl. IO A C2~C6 alkenyl group may be linear or branched. In a di-Ci-Cs-alkylarnino group, the
alkyl moieties may be the same or different
In one embodiment of the invention, when E represents C(0)NH, then X is S, SO or
so2.
15
In another embodiment of the invention, when E represents NHC(O), then X is 0 or
NR13.
12 Preferably, R and R each independently represent a hydrogen or halogen atom, or
1 2
20 an amino, nitro, C1-C4 alkyl or trifluoromethyl group (but R and R may not both
simultaneously represent a hydrogen atom).
1 2
More preferably, R and R each independently represent a hydrogen, chlorine or
1 2
bromine atom, or an amino, nitro, C^-C^ alkyl or trifluoromethyl group (but R andR
25 may not bom simultaneously represent a hydrogen atom).
Most preferably, R1 and R2 each independently represent a hydrogen or chlorine atom (but Rl and HC may not both simultaneously represent a hydrogen atom).

WO 01/44170

PCT/SE0O/02503

R represents a Cj-Cg alkyl group, for example a linear C^-Cg aikyl group such-as
CH2, (CH2)2, (CH2)3 or (CH2)4.
Preferably X represents an oxygen atom or, especially, a group NR J.
R represents hydrogen, or R represents CpCg alkyl or C2-C6 alkenyl (e.g.
ethenyl or -CH2CH=CH2), each of which may be optionally substituted by at least one substituent, e.g. one, two or three substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, (di)-Ci-C6-alkylamino (e.g. methylamino, ethylamino, dimethylamino or diethylamino), -Y-R ,
2 j and a 5- or 6-membered heteroaromatic ring comprising 1,2, 3 or 4 heteroatoms independently selected from nitrogen, oxygen and sulphur which heteroaromatic ring may itself be optionally substituted by at least one substituent, e.g. one or two substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl and CpCs, preferably C]-C4, alkyl, e.g., imidazolyl (such as imidazol-1-yl or imidazol-4-yl),
1-methyliniidazolyl (such as l-methylirnidazol-4-yl), 2,3,5-triazolyl and 2,3,4,5-tetrazolyl.
Preferred compounds are those in which R represents an optionally substituted CL-C6 alkyl group. A preferred optional substituent is -Y-R .
6 -77
When Y represents SO or S02, R represents a group -R Z where R represents a
so inn
C2-C6 alkyl group and Z represents an -OH, -C02H, -NRR, -C(0)NR1UR1 or
-N(R12)C(0)-CrC6 alkyl group.
When Y represents an oxygen or sulphur atom or a group NH, R may
7
represent a group ^-R Z as defined above (particularly -(CH2O2OH or -(CK^OHl),

WO 01/44170

PCT/SEOO/02505

or R6 may represent hydrogen, CrC6 alkyl (e.g. methyl, ethyl, n-propyL isopropyl or t-butyl), Cj-Cg alkylcarbonyl (e.g. methylcarbonyl, ethylcarbonyl, n-propylcarbonyl or t-butylcarbonyl), Ci-Cg alkoxycarbonyl (e.g. methoxycarbdnyl, ethoxycarbonyl, n-propoxycarbonyl or t-butoxycarbonyl), -C(0)NR14R15, -CH2OC(0)R16, -CH2OC(0)OR17 or -C(0)OCH2OR18-
Y is preferably an oxygen or sulphur atom or a.group NH.
In one embodiment of the invention, Y represents an oxygen or sulphur atom or a 10 group NH and R represents -(CH^OH, -(CH^OH, hydrogen, methyl, isopropyl, mediylcarbonyl or t-butylcarbonyl. In another embodiment, Y represents oxygen and R represents hydrogen.
8 9 10 11 12
Preferably R , R , R , R and R each independently represent a hydrogen atom
is or a C1-C4 alkyl group.
13 R represents hydrogen, C3-C8, preferably C3-C6, cycloalkyl, C3-Cg, preferably
C3-C6, cycloalkyhnethyl, or R J represents a CrC6 alkyl group optionally substituted by at least one substituent, e.g. one, two or three substituents independently selected from 20 hydroxyl and Cj-Cg alkoxy. Examples of preferred groups R include hydrogen, -(CH^OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl,
cyclopropyl, cyclopentyl, cyclohexyl and cyclohexylmethyl.
R ,R ,R ,R andR each independently represent a Ci-C6, or Cj-C^ alkyl group.
25
Preferred compounds of the invention include: 2-(^oro-5-[[2-(>hydroxy-emylammo (tricyclo[33.1.13,7]dec-l-ylmethyl)-benzamide, 2-Cttoro-5-[[2
WO 01/44170

PCT/SEOO/02505

6
2-Chloro-5-[(3-hydroxy-2,2-dimethylpropylamino)methyl]-iV-{tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide,
2-CWoro-5-[(5-hydroxypentylamino)methyl]-AL(tricyclo[3.3.1. l3,7]dec-l-ylmethyl)-
benzamide,
5 2-CMoro-54[2-[(2-hyciroxyethyltbJo)ethylamino3methyli-A/'-(tricycIo[3.3.1.13J]dec-
1 -ylmethyl)-benzamide,
2-Chloro-5-[3-[(2-hydroxyethyI)amino]propyll-A'-{tricyclo[3.3.1.13>7]dec-1 -ylmethyl)-benzamide,
2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-Ar-(tiicyclo[3.3.1. l3,7]dec-l-10 ylmethyl)-benzamide,
2-CMoro-543Kmethylamiiio)propyl]-iV"-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl> benzamide,
2-CUoro-5-[3-[(l-methylethyl)amino]propyl]-Ar-(tricyclo[3.3.Ll3'7]dec-l-yb3ie%l)-
benzamide,
15 5-[3-[(2-Amino-2-methylpropyl)amino]propyl]-2-chloro-iV'-(tricyclo[3.3.1. l3,7]dec-l-
ylmethyl)-benzamide,
2-Chloro-5-[3-[(4-hydroxybutyl)ainino]propyl]-iV-(tricyclo[3.3.1.13'7]dec-l-
ylmethyl)-benzamide,
2-CUoro-5-[3-[(2-hydroxy-2-methylpropyl)amino]propyl]-iV'-(tricyclo[3.3.1.13,7]dec-2,0 l-ylmethyl)-benzamide,
2-Chloro-5-[3-[[2-(methylamino)ethyl]amiao]propyl]-N'(tricyclo[3.3.1.13-7]dec-l-ylmethyl)-benzamide, dihydrochloride salt,
(S)-2-CbJoro-5-[3-[(2-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13J]dec-l-
ylmethyl)-benzamide, hydrochloride salt,
25 (R)-2-Chloro-5-[3-[(2-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -
ylmethyl)-benzamide, hydrochloride salt,
(R)-2-Chloio-5-[3-[(2-hydroxy- l-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.13'7]dec-l-ylmethyl)-benzamide, hydrochloride salt,
2-CWoro-5-[3-[[2-hydroxy-l^ydroxymethyl)-l-methylethyl]amino]propyl]-N-30 (tricyclo[3.3.1.13'7]dec-l-ylmethyl)-benzamide,

WO 01/44170
7
5-[3-[[2-(Acetylainino)ethyl]aiiiino]propyl]-2-chloro-N-(tricy clo[3.3.1.13-7]dec-l -
ylmethyl)-benzamide, hydrochloride salt, .
2-CWoro-5-[3^[2-(die%lamino)ethyl]amino]pTopyl]-N-(tricyclo[3.3.1.13-7]dec-1 -
ylmethyl)-benzamide, dihydrochloride salt,
5 2-Chloro-5-[3-[(3-methoxypropyl)ainino]propyl]-N-(tricyclo[3.3.1.13,7]dec-l-
ylmethyl)-benzamide, hydrochloride salt,
2-CMoro-5-[3-[(3-hydroxy-3-methylbutyI)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-benzamide, hydrochloride salt,
2-Chloro-5-[3-[(2-methoxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13>7]dec-1-io ylmethyl)-benzaniide, hydrochloride salt,
2-Chloro-5-[[3-(methyIamino)propoxy]methyl]-N-(tricyclo[3.3.1. l3'7]dec-l-ylmethyl) benzamide,
2-CbJoro-5-[[2-[(2-hydroxyethyl)amiiio]ethoxy]rnethyl]-N-(tricyclo[3.3.1.13,7Jdec-l -
ylmethyl)-benzarnide, acetic acid salt,
l s 2-CMoro-5-[[2-[(3-hydtoxypropyl)amino]ethoxy]methyl]-N-(tricyclo[3.3.1.13'7]dec-
l-ylmethyl)-benzamide, acetic acid salt,
2-Chloro-5-[[[3-[(l -methylethyl)amino]propyl]amino]methyl]-N-
(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-benzamide,
5-[[(3-Aminopropyl)amino]methyI]-2-chloro-N-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-
20 benzamide,
2-Chloro-5-[[[2-[( 1 -me%Iethyl)amino]ethyl]aniiiio]methyl]-N-(tricyclo [3.3.1.13,7]dec-1 -ylmethyl)-ben2amide,
3-[[3-[4-Cbioro-3-[[(tricyclo[3.3.1 .l3,7]dec-l-ylniethyl)amino]-carbonyl]phenyl]propyl]amino]propaiioic acid, 2,2-dimethylpropyl ester, trifluoroacetic
25 acid salt,
5-(2-Aminoethyl)-2-chloro-N-(tricyclo[3.3.1. l3,7]dec-1 -ylmethyl)benzamide, 2-Chloro-5-[3-[(2-hydax)xyemyl)peiitylarrdno]propyl]-NKtricyclo[33.1.13-7]dec-l-
ylmethyl)-benzamide,
2-Cbioro-5-[3-(methyl-2-propenylaniiiio)propyl]-N-(tricyclo[3.3.1.13-7]dec-l-
30 ylmethyl)-benzamide,

WO01/44170 PCT/SEOO/02505
2-CMoro-5-[3-[[2-(dimethylamino)ethyl]methylamino]propyl]-N-(tiicycIo[3.3.1.13'7]dec-l-ylmethyl)-benzamide,
5-[3-(Butylethylamino)propyl]-2-chloro-N-(tricyclo[3.3.1.13>7Jdec-1 -ylmethyl)-
benzamide,
5 2-Chloro-5-[3-(methylpentylamino)propyl]-N-(tricyclo[3.3. l.l3J]dec-l-ylmethyl)-
benzamide,
2-Chloro-5-[34[2 2-Chloro-5-[3-[(2-hydroxyethyl)methylamino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -10 ylmethyl)-benzamide,
2-Chloro-5-[3-(dipropylamino)pro^yl]-N-(tricyclo[3.3.1.13'7]dec-l-ylmethyl)-benzamide,
2-Chloro-5-[3-[(2-hydroxyethyl)(l-methylethyl)amino]propyl]-N-
(tricyclo [3.3.1.13,7]dec-1 -ylmethyl)-benzamide,
15 5-[3-putyl(2-hydroxyethyl)amino]propyl]-2-chloro-N-(tricyclo[3.3.1.13,7]dec-l-
ylmethyl)*-benzamide,
2-Chloro-5-[3-(diethylamino)propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide,
2-CUoro-5-[3-(dimethylamino)propyl]-N-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-
20 benzamide, . '
5 2-Chloro-5-[3-[(2-hydroxyetb.yl)propylainino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -
ylmethyl)-benzamide, .
25 2-CMoro-5-[3-[ethyl(2-hydroxyethyI)amino]propyl]-N-(tricyclo.[3.3.1.13'7]dec-l-
ylmethyl)-benzamide,
2-CbJoro-5-[3^dibutyIamino)propyI]-N-(tricyclo[3.3.1.13-7]dec-l-ylmethyl)-benzamide,
2-CWoro-5-[3-(ethyIpropylamino)propyl]-N-(tricyclo[3.3.1.13-7]dec-l-ylmethyl)-30 benzamide,

WO 01/44170 PCT/SEOO/02505
9
2-CUoro-5-[3-[methyl( 1 -methylethyI)amino]propyl]-N-(tricyclo[3.3.1.13'7]dec-1 -
ylmethyl^benzamide,
2-CMoro-5-[3-[[3-(dimethylamino)propyl]methylaminb]propyl]-N-
(tricyclo[3.3.1.13,7]dec-l-yimethyl)-benzamide,
5 2-Chloro-5-[3-[cyclohexyl(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-
1-ylmethyl)-benzamide,
2-Cbloro-5-[3-(cyclohexylmethylainino)propyr]-Nr(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide,
2-Qiloro-5-[3-(cyclohexylamiiio)propyl]-N-(tricyclo[3.3.1.13-7]dec- 1-ylmethyl)-10 benzamide,
2-Chloro-5-[3-[[ 1 -(hydroxymethyl)-2,2-dimethylpropyl]amino]propyl]-N-(tricyclo[3.3.1. lJ,7]dec-1-ylmethyl)-benzamide,
2-Chloro-5-[3-(cyclopropylamino)propyl]-N-(tricyclo[3.3.1.13'7]dec-1 -ylmethyl)-
benzamide,
15 2-CUoro-5-[3-[[2Kdimethylainino)ethyI]aniirio]propyl]-N-(tricyclG[3.3.1.13-7]dec-1 -
ylmethyl)-benzamide,
2-Chloro-5-[3-[(3 -hydroxy-2,2-dimethylpropyl)amino]propyl]-N-(tricy clo[3.3.1.13,7]dec-1-ylmethyl)-benzamide, ■
2-CHoro-5-[3-[( 1,1 -dimethylethyl)amino]propyt]-N-(tricyclo [3.3.1. l3'7]dec-1-20 ylmethyl)-benzamide,
2-CUoro-5-[3-[[3-(dimethylamino)propyl]ainiiio]propyl]-N-(tricyclo[3.3.1.13-7]dec-1-ylmethyl)-benzamide,
2-CbJoro-5-[3-(cyclopentylamino)propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-
benzamide,
25 2-Chloro-N-(tricycIo[3.3.1. l3-7]dec- l-yImethyl)-5-[3-[(l ^,2-
trimethylpropyl)amino]propyl]-beii2amide,
5-[3^utylamino)propyl]-2-chlc>rb-N-(tricyclo[33.1. l3-7]dec-l -ylmethyl>benzamide5 2-CbJoro-5-[3-[[l-(hydroxyme&yl>2-methylpropyl3ainino]propyI3-N-.
(tricyclo[3.3.1.13J]dec-l-ylmethyl)-benzamide,

WO 01/44170 PCT/SEOO/02505
10
2-Chloro-5-[3-[( l-methylpropyI)amino]propyI]-N-(tricyclo[3.3.1. l3,7]dec-1-ylmethyl)-benzamide,
2-CWoro-5-[3-[[2-(methylthio)ethyl]amino]propyl]-N-(tricyclo[3.3.1. l3J]dec-1 -ylmethyl)-benzamide,
2-Chloro-5-[3-[(2-hydroxy-1,1 -dimethylethyl)amino]propyI]-N-
(tricyclo [3.3.1.13,7]dec-1 -ylmetiiyl)-benzamide,
2-Chloro-5-[3-[(cycIohexylmethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-benzamide,
2-Chloro-5-[3-(2-propenylamino)propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide,
2-Chloro-5-[3-[(2-fluoroethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-l -ylmethyl)-benzamide,
2-Chloro-5-[3-[(2-methoxy-1 -methylethyl)amino]propyl]-N-(tricyclo[3.3.1.13>7]dec-1 -ylmethyl)-benzamide,
2-Chloro-5-[3-[3-(methylaniino)propoxy]propyl]-N-(tricyclo[3 3.1.13,7]dec-1 -ylmethyl)benzamide, dihydrochloride salt, •
5-[[[( 1 -AminocycIoprppyl)methyl](2-hydroxyethyl)amino]methyl]-2-chloro-N-(tricyclo[33.Ll3,7]dec-l-ylmethyl)-ben2amide,
5-[[(2-Hydroxyethyl)[2-(methylamino)ethyl]amino]inethyl]-2-inethyl-N-(tricyclo [3.3.1.13,7]dec-1 -ylmethyl)-benzamide,
2-CWoro-5-[3-[[2-(l-methyl-lH-imidazoM-yl)ethyl]amino]prQpyl]-N-(tricyclo [3.3.1.13,7]dec-1 -ylmethyl)benzamide,
2-CWoro-543-[[2-(lH-imidazol^yl)ethyl]amino]propyl]-N-(tricyclo[3.3.1.13'7]dec-l -ylmethyl)benzamide,
2-Chloro-5-[3-[[3-( 1 H-imidazol-1 -yl)propyl]amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)benzamide, and pharmaceutically acceptable salts and solvates thereof.
The present invention further provides a process for the preparation of a compound of formula (I) as defined above which comprises:

WO 01/44170 PCT/SEOO/02505
11
(a) when X represents an oxygen or sulphur atom or a group NR13, reacting a compound
of general formula

(in)
5 wherein L represents a leaving group (e.g. a halogen atom or trifluoromethanesulphonate
I 2 4
group) and D, E, R , R and R are as defined in formula (I), with a compound of general
formula

X' (IV)
10
13 5
wherein X' represents an oxygen or sulphur atom or a group NR , and R is as defined in
formula (I), optionally in the presence of a suitable silver salt (e.g. silver
trifluoromethanesulphonate); or
is (b) when X represents SO or S02, reacting a corresponding compound of formula (I) in which X represents a sulphur atom with a suitable oxidising agent; or
(c) when X represents a group NR , , reacting a compound of general formula

WO 01/44170 PCT/SEOO/02505
12


R\ R20-CHO

(V)

20 " 1 2
wherein R represents a bond or Ci~C5 alkyl group and D, E, R andR are as defined in
formula (I), with a compound of general formula
5
K ^R5
N'
.13 *
1 (VI);
5 13 '
wherein R and R are as defined in formula (I), in the presence of a reducing agent (e.g.
sodium triacetoxyborohydride);
10 and optionally after (a), (b) or (c) converting the compound of formula (I) obtained to
a pharmaceutically acceptable salt or solvate thereof.
The processes of me invention may conveniently be carried out in a solvent, e.g. an organic solvent such as dichloromethane, 1, 2-dichloroethane or tetrahydxofuran, at 15 a temperature, e.g. in the range from 0 to 200 °C, preferably in the range from 0 to 150 °C. The oxidising agent used in (b) above may, for example, be 3-chloroperoxybenzoic acid or potassium peroxymonosulphate, commercially sold under the trade mark "OXONE".
20
Compounds of formula (V) in which R represents a bond may be prepared by
20 reacting a compound of general formula

WO 01/44170 PCT/SE00/02505
13

(VII)
1 2
wherein Hal represents a halogen atom such as bromine and D, E, R and R are as defined
in formula (I), with a base such as t-butyllithium and then with a fonnylating agent such as
dimethylformamide.
Compounds of formula (VII) may conveniently be prepared by reacting a compound of general formula


25
wherein R represents NH2 or C02H and D is as defined in formula (I),
rvni)
1 and D is as lo with a compound of general formula


wherein R represents C02H or NH2, and R , R and Hal are as defined in formula (VH)
above. -" . • .
20
is Compounds of formula (V) in which R represents a C pCs alkyl group may be
prepared, for example, by reacting a corresponding compound of formula (V) in which R represents a bond with (memoxymethyl)diphenylphosphineoxide in the presence of a base, or, with a compound of general formula

WO 01/44170 PCT/SE00/02505
14


RO ^ ROOpXCH^ ^^OR'
II OR'
(X) in which n is 0, 1, 2 or 3 and R and R' independently represent CyC§ alkyl groups,
followed by hydrogenation.
5
-■ 20 Alternatively, compounds of formula (V) in which R represents a C2-C5 alkyl
group may be prepared by reacting a compound of formula (VII) with an alkenol (e.g. 2-propen-l-ol (allyl alcohol), but-3-enol, pent-4-enol or hex-5-enol) in the presence of a palladium catalyst, optionally followed by a hydrogenation reaction and an oxidation 10 reaction using, for example, Dess-Martiniperiodinane reagent (these last two steps are not required when the alkenol is allyl alcohol).
20 As a further alternative, compounds of formula (V) in which R represents a C2-C5
alkyl group may be prepared by reacting a compound of formula (VII) with an alkenoate
is ester (e.g. methyl acrylate or ethyl acrylate) in the presence of a palladium catalyst such as
palladium acetate, followed by reduction of the ester group to a hydroxyl group and then
oxidation to the aldehyde with an oxidising agent (e.g. Dess-Martin periodinane reagent).
Compounds of formula (I) in which R represents a C2-C6 alkyl group substituted by
fi • 6 7
20 a group -Y-R where Y represents O, S or NH and R represents a group -R Z as defined
above, may be prepared by reacting a corresponding compound of formula (I) in which R
represents a C2-C$ alkyl group substituted by a hydroxyl group with a hydroxyl activating
agent (such as methanesulphonyl chloride) in the presence of a base (such as
triethylamine), followed by reaction with a compound of formula HO-R Z, HS-R Z or
triethylan
25 H,N-R7Z
Compounds of formula (I) wherein E represents a group NHC(O) may be prepared from a compound of general formula

WO 01/44170 PCT/SEOO/02505
15

H02C
R' m
wherein R , R and RJ are as defined in formula (I) and X represents O, S or NR , by
reaction with adamantylmethylamine or adamantylethylamine, in the presence of a 5 coupling agent such as l,r-carbonyldiimidazole.
Compounds of formula (I) wherein E represents a group C(0)NH may be prepared from a compound of general formula „



io R (XII)
wherein R , R and RJ are as defined in formula (I) and X represents O, S or NR , by
reaction with adamantylacetyl chloride or adamantylpropanoyl chloride in the presence of a base such as triemylarnine.
u Compounds of formula (XI) can be prepared from a compound of general formula


H02C
2 • ■
wherein L represents a leaving group (such as a halogen atom or
CXffl)
latom trifluoromethanesulphonate group) and R1, RZ and RH are as defined in formula (I), with a

WO 01/44170

PCT/SEOO/02505

16
compound of formula (TV) as defined above, optionally in the presence of a silver salt such as silver trifluoromethanesulphonate.
Compounds of formula (XII) can be prepared from a compound of general formula.


(XIV) wherein L represents a leaving group (such as a halogen atom or
1 O A
trifluoromethanesulphonate group) and R , R and R are as defined in formula (I), with a compound of formula (IV) as defined abqye, optionally in the presence of a silver salt such as silver trifluoromethanesulphonate.
10
It will be appreciated that certain compounds of formula (I) may be converted into further compounds of formula (I). For example, compounds of formula (I) in which -Y-R6 represents -OH can be converted to compounds in which Y is O and R6 is CrC6 alkoxycarbonyl, by reaction with an acylating agent Furthermore, compounds of. is formula (I) in which X represents NR13 and R13 is other than hydrogen, for example, a cyclohexyl group can be prepared by reacting a compound of formula (I) in which X represents NH with cyclohexanone in the presence of a reducing agent such as sodium triacetoxyborohydride.
20 Compounds of formula (III), (IV), (VI), (VIII), (DQ, (X), (XTO) and (XTV) as well
as compounds HO-R Z, HS-R Z and H2N-R7Z are either commercially available, are
well known in the literature or may be prepared easily using known techniques.
It will be appreciated by those skilled in the art that in the processes of the present 25 invention certain functional groups such as hydroxyl, carboxyl, aldehyde, carbonyl or amino groups in the starting reagents or intermediate compounds may need to be protected

WO 01/44170

PCT/SE00/02505

17
by protecting groups. Thus, the preparation of the compounds of formula (I) may involve at a certain stage the removal of one or more protecting groups.
The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic .Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1991).
The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate,
kk.
methanesulphonate or/>-toluenesulphonate, or an alkali metal salt such as a sodium or potassium salt
Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.
The compounds of the present invention are advantageous in that they possess pharmacological activity and have utility as modulators of P2X7 receptor activity. They are therefore indicated as pharmaceuticals for use in the treatment or prevention of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, hyperrespqnsiveness of the airway, chronic obstructive pulmonary disease (COPD), bronchitis, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, neurodegenerative disease, Alzheimer's disease, meningitis, osteoporosis, bum injury, ischaemic heart disease, stroke, peripheral vascular disease and
varicose veins.

WO 01/44170

PCT/SE00/02505

18
Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
5 In another aspect, the invention provides the use of a compound of formula (I), or a
pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.
In the context of the present specification, the term "therapy" also includes io "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.
Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, 15 the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the. disease or condition.
20 The invention further provides a method of effecting immunosuppression (e.g. in the
treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis, psoriasis, pulmonary disease, e.g. COPD or bronchitis, or diseases of the central nervous system, e.g. Alzheimer's disease or stroke) which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate
25 thereof, as hereinbefore defined to a patient
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disease or condition indicated. For effecting immunosuppression, the daily dosage of 30 the compound of formula (I) will typically be in the range from 0.001 mg/kg to 30 mg/kg.

WO 01/44170 FCT/SE00/U2505
19
The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active 5 ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being IO based on total composition.
Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or is carrier.
The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined with a 20 pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical composition of the invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafiuorpalkane aerosols and dry powder formulations; or systemically, e.g. by oral 25 administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdennally.
The present invention will now be further explained by reference to the following 30 illustrative examples.

WO 01/44170

PCT/SE00/02505

20
Example 1 2-Chloro-5-[[2-(2-hydroxy^thylainrao)^thylan^
l-ylmethyl)-benzamide dihydrochloride .


OH


10
15

a) 5-Bromo-2-cnloro-Ar-(tricyclo[3J.l.l3J]dec-l-ylmethyl)-ben2amide
To a suspension of 5-bromo-2-chlorobenzoic acid (5.00 g) in dichloromethane (25 ml) at 0°C was added oxalyl chloride (3.7 ml) and DMF (5 drops), The resulting mixture was stirred at room temperature under a nitrogen atmosphere for lh, then concentrated under reduced pressure to yield a solid. The solid was dissolved in dichloromethane (20 ml) and added dropwise to a solution of 1 -adamantanemethylamine (3.36g) and A^iV^risopropylethylamine (5.55 ml) in dichloromethane (20 ml). The resulting solution was allowed to stir at room temperature under a nitrogen atmosphere for 20hs. The reaction mixture was diluted with dichloromethane and washed with water, 10% aqueous potassium carbonate, 10% aqueous potassium hydrogen sulfate and saturated brine. The organic phase was then dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the subtitled compound as a solid (7.84 g).



20

MS (APCI +ve) 382/384/386 (M+H)+

WO 01/44170 PCT/SE00/02505
.21
'H NMR (DMSO-d6) 5 8.42 (1H, t); 7.63 (1H, dd); 7.57 (lH,_m); 7.45 (1H, d), 2.93 (2H, d); 1.94 (3H, s, br); 1.69-1.58 (6H, m); 1.51 (6H, s).
b) 2-Chloro-5-formyl-iV-(tricyclo [3.3.1.13'7] dec-l-ylmethyl)-benzamide
A solution of 5-bromo-2-chloro-JV-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)^benzamide
(3.25 g, Example 1 a) in tetrahydrofuran (150 ml) was cooled to —78°C under a nitrogen '
atmosphere. A solution of 1.4M methyllithium in diethyl ether (6.1 ml) was added to this
solution over 2min.. The mixture was stirred at —78°C for 1 Omin., then a 1JM solution of
^err-butyllithium in pentane (10.0 ml) was added dropwise. The mixture was stirred at-
78°C for a further lOmin., then dimethylformamide (1.0 ml) was added. The resulting
solution was stirred at -78°C for 30min., quenched with saturated aqueous ammonium
•b. chloride solution (100 ml) and extracted with ethyl acetate. The combined extracts were
dried over sodium sulfate, filtered, and the filtrate concentrated under reduced pressure to
give the subtitled compound as a solid (2.76 g).
MS (APCI +ve) 332/334 (M+H)+
'H NMR (DMSO-dj) 5 10.04 (1H, s); 8.49 (1H, t); 7.96-7.91 (2H, m); 7.74 (1H, d); 2.96
(2H, d), 1.95 (3H, s); 1.64 (6H, m); 1.53 (6H, d).
c) 2-CbJoro-5-[[2-{2-hydroxy-ethylanimo)-ethylamino]-methylI-Ar-(tricycIo[3^.1.13,7]dec-l-yImethyl)-benzamide dihydrocbJoride
A mixture of 2-cMoro-5-formyl-./V'-(tricyclo [3.3.1.13,7] dec-l-ylmethyl)-benzamide (0.244 g, Example lb), 2-(2-ammoemylamino)-ethanol (0.154 g), p-toluenesulfonic acid (0.005 g) and toluene (30 ml) were refluxed together under Dean-Stark conditions for 3hs, cooled and concentrated under reduced pressure to give an oil. This was dissolved in ethanol (30 ml) and cooled to 0°C under a nitrogen atmosphere. Solid sodium borohydride
(0.030 g) was. added portionwise to this and the mixture stirred at room temperature for 3 Omin. The mixture was concentrated under reduced pressure and the residue purified by column chromatography over silica gel (eluting with 7:3:0.3 dichloromethane/ methanol/ 35% aqueous ammonia) to give the free base. This was dissolved in methanol (10 ml) and

WO 01/44170

PCT/SEOO/02505

22
treated with 4M hydrochloric acid in dioxane (4 ml) to give a solid precipitate. This was filtered off and washed with diethyl ether to afford the title compound as a solid (0.165 g).
MS (APCI +-ve) 420/422 (M+H)+ 5 lH NMR (DMSO-d6) 5 8.36 (1H, t); 7.61-7.57 (3H, m); 5.31 (1H s, br); 4.22
(2H, s, br); 3.68 (2H, s, br); 3.05 (2H, s, br); 2.95 (2H, d); 1.95 (3H, s, br); 1.69-1.59 (6H, m); 1.53(6H,s,br).
Example 2
10 2-CWoro-5-[[2-(2-hydroxyethoxy)ethylamino]methyI]-A^-(tricyclo[3J.l.l3'7)dec-l-ylmethyl)-benzamide




15
20

To a solution of 2-chloro-5-formyl-iV'-(tricyclo [3.3.1.13J] dec-1 -ylmethyl)-benzamide (0.150 g, Example lb) and 2-(2-aminoethoxy)ethanol (0.065 ml) in 1,2-dichloroethane (6 ml) was added sodium triacetoxyborohydnde (0.134 g), and the mixture was stirred overnight at room temperature. Water (20 ml) and dichloromethane (20 ml) were added and the layers were partitioned. The organics were washed with brine (30 ml) dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure The residue was purified by NPHPLC during with a gradient of 0-10% ethanol in dichloromethane to give the title compound as a white powder (0.016 g).

MS (APCI +ve) 421/423 (M+H)'

WO 01/44170 PCT/SE00/02505
23
'H NMR (DMSO-d6) 5 8.29 (1H, s, br); 7.42-7.34 (3H, m); 4.60 (1H, s, br); 3.71 (2H,.s);
3.47 (4H, s); 3.40 (2H, d); 2.93 (2H, d); 2.63 (2H, d); 1.94 (3H, s); 1.64 (6H, q); 1.52 (6H, s).
Example 3
2-CUoro-5-[(3-hydroxy-2^-dimethylpropylamino)methyl]-A^-(tricyclo[33.1.13'7]dec-l-ylmethyl)-benzamide


OH

Prepared according to die method described in Example 2 from 2-chloro-5-formyl-iV-(tricyclo [3.3.LI3,7] dec-l-ylmethyl)-benzamide (0.150 g, Example lb), 3-amino-2,2-dimemylpropanol (0.093 g) and sodium triacetoxyborohydride (0.134 g) in 1,2-dichloroethane (6 ml). After work-up, the residue was purified by NPHPLC eluting with a gradient of 0-10% ethanol in dichloromethane to give the title compound as a white powder (0.035 g).
MS (APCI +ve) 419/421 (M+H)+
'H NMR (DMSO-ds) 5 8.29 (1H, t); 7.41-7.34 (3H, m); 4.60 (1H, s, br); 3.70 (2H, s); 3.16
(2H, s); 2.93 (2H, d); 2.29 (2H, s); 1.94 (3H, s, br); 1.63 (6H, q); 1.52 (6H, d); 0.80 (6H, s).
Example 4
2-CMoro-5-[(5-hydroxypentylam^
benzamide

WO 01/44170

PCT/SEOO/02505

24




10

A mixture of 2-chloro-5-formyl-A^-(tricyclo [3.3.l.l3,7] dec-l-ylmethyl)-benzamide (0.100 g, Example lb), 5-amino-l-pentanol (0.031 mg) and titanium(IV) isopropoxide (0.111 ml) was stirred under nitrogen for lh at room temperature. The viscous solution obtained was diluted with absolute ethanol (2 ml). Sodium cyanoborohydride (0.013 g) was added, and the solution was stirred for 20h at room temperature. Water (5 ml) was added with stirring and the resulting precipitate was filtered and washed with ethanol. Th«
filtrate was concentrated under reduced pressure. The crude product was dissolved in dichloromethane (20 ml) and filtered to remove the remaining inorganic residues. The filtrate was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by NPHPLC eluting with a gradient of 0-10% ethanol in dichloromethane to give the title compound as a white powder (0.031 g).



15

MS (APCI +ve) 419/421 (M)+
!H NMR (DMSO-d6) 5 8.28 (1H, t); 7.41-7.34 (3H, m); 5.30 (1H, s); 4.31 (1H, t); 3.67 (2H, s); 3.37-3.32 (2H, m); 2.93 (2H, d); 2.46-2.42 (2H, m); 1.94 (3H, s); 1.63 (6H, q); 1.52 (6H, s); 1.43-1.36 (2H, m); 1.32-1.28 (2H, m); 1.27-1.21 (2H, m).

20 Example 5
2-Chloro-5-[[2^2-hydroxyethyltWo)etfaylamino]methyl]-^(tricyclo[33.1.13,7ldec-l-
ylmethyl)-benzamide

WO 01/44170

PCT/SE00/02505

25



Prepared according to the method described in Example 2 from 2-cMoro-5-formyl-N-(tricyclo [3.3.1.13'7] dec-l-ylmethyl)-benzarnide (0.800 g, Example lb), 2-(2-
5 aminoethylthio)ethaiiol (0.584 g) and sodium triacetoxyborohydride (0.715 g) in 1,2-
dichloroethane (15 ml). After work-up, the residue was purified by NPHPLC eluting with a gradient of 0-10% ethanol in dichloromethane to give the title compound as a white powder (0.536 g).
10 MS (APCI+ve) 437/439 (M)+
IH NMR (DMSO-ds) 5 8.29 (IH, t); 7.42-7.35 (3H, m); 4.78 (IH, s, br); 3.71 (2H, s); 3.50 (2H, t); 2.93 (2H, d); 2.68-2.58 (4H, m); 2.56-2.52 (2H, m); 1.94 (3H, s, br); 1.63 (6H,q); 1.52 (6H,s).
is Example 6
2-Chloro-5-[3-[(2-hydroxyethyI)amino]propylJ-iV-(tricyclo[33.1.13*7]dec-l-ylinethyl> benzamide, acetate salt


WO 01/44170 PCT/SE00/02505
26
a) (2J£}-3-[4-Chloro-3-[[(tricycIo[33.1.13'7]dec-l-ylmethyI)amino]carbonyl]phenyI]-
2-propenoic acid, methyl ester
5-Bromo-2-chloro-iV-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)- benzamide (5g), methyl . 5 acrylate (1.4ml), triethylamine (2.1ml), palladium acetate (0.070g) and tri-orthotolyl
phosphine (0.185g) were combined in N,N-dimethylformamide (20ml). The mixture was heated in a sealed tube under nitrogen at 90°C for 24h. After cooling, the reaction mixture was partitioned between dichloromethane and dilute hydrochloric acid, the mixed phases were filtered through celite and the phases separated. The organic layer was washed with io dilute hydrochloric acid and brine, dried over magnesium sulfate and concentrated under reduced pressure to give a residue which was triturated with diethyl ether and filtered to yield the subtitled compound as an off white solid (4.1g).
MS (APCI +ve) 388/390 (M+H)+ 15 *H NMR (CDCy 5 7.84 (IH, d); 7.64 (IH, d); 7.49 (IH, dd); 7 A3 (IH, d); 6.45 (IH, d); . 6.24 (IH, t, br); 3.81 (3H, s); 3.19 (2H, d); 2.02 (3H, s); 1.70 (6H, q); 1.59 (6H, d).
b) 4-Chloro-3-[[(tricyclo[33.1 .l3,7]dec-l-ylmethyl)amino] carbonyl]-benzenepropanoic acid, methyl ester
20 5% Rhodium on carbon (0.40g) was added to a solution of (2£)-3-[4-chloro-3-
[[(tricyclo[3.3.1.13,7]dec-1 -yImemyl)amino]carbonyl]phenyl]-2-propenoic acid, methyl ester (Example 6a, 2.2g) in ethyl acetate / dichloromethane (4:1) (160ml) and the mixture hydrogenated at 3 bar for 24h. The catalyst was removed by filtration and the filtrate concentrated to give the subtitled compound as an oil (2.3g).
25
MS (APCI +ve) 390/392 (M+H)+
lH NMR (CDC13) 8 7.55 (IH, d); 731 (IH, d); 7.20 (IH, dd); 6.26 (IH, t, br); 3.68 (3H, s); 3.17 (2a d); 2.95 (2H, t); 2.63 (2H, t); 2.02 (3H, s); 1.70 (6H, q); 1.59 (6H, d).

WO 01/44170 PCT/SE00/02505
27
c) 4-ChIoro-3-[[(tricyclo[3J.l-l3,7]dec-l-yImethyl)amino]carbonyI]-benzenepropanoic acid
A solution of sodium hydroxide (0.475g) in water (30ml) was added to a solution of 4-chloro-3-[[(tricyclo[3.3.1 .l3,7]dec-l-yhnethyl)amino]carbonyl]-benzenepropanoic acid, methyl ester (Example 6b, 2.3g) in methanol (30ml). After 5h the reaction mixture was reduced to half volume in vacuo and acidified with dilute hydrochloric acid. A white solid precipitated and was collected by filtration and dried in vacuo at 50°C, to give the subtided compound (1.2g).
MS (APCI +ve) 376/378 (M+H)+
'H NMR (DMSO-d6) 5 11.18 (1H, s); 8.28 (1H, t); 7.37 (1H, d); 7.28 (1H, dd); 7-26 (1H,
d); 2.92 (2H, d); 2.82 (2H, t); 2.54 (2H, t); 1.94 (3H, s); 1.63 (6H, q); 1.52 (6H, s).
d) 2^hIoro-5-(3-hydroxypropyI)-Ar-(rricycIo[33.1.13,7]dec-l-yImethyI)-beiizamide
Isobutylchloroformate (0.575ml) and triethylamine (0.63ml) were added to a solution of 4-chloro-3-[[(tricyclo[3.3.1.13,7]dec-1 -ylmemyl)amino]carbonyl]-berizenepropanoic acid (Example 6c, 1.64g) in tetrahydrofuran (30ml) at 0°C. After lh the precipitates were removed by filtration and the filtrate added portionwise to a solution of sodium borohydride (0.18g) in water (10ml) at 0°C. After a further lh the reaction mixture was poured onto dilute hydrochloric acid and extracted with etiiyl acetate. The organic phase was extracted twice with dilute hydrochloric acid, twice with saturated sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced pressure to give a residue. Purification by silica gel chromatography (eluting with dichloromethane / methanol 96:4); yielded the subtitled compound as a solid (1.3g).
t
MS (APCI +ve) 362/364 (M+H)+
"H NMR (CDC13) 8 7.55 (1H, d); 731 (1H, d); 7.19 (1H, dd); 6.28 (1H, s, br); 3.66 (2H, t); 3.17 (2H, d); 2.72 (2H, t); 1.92 (3H, s); 1.88 (2H, quia); 1.68 (6H, q); 1.59 (6H, s); 128 (1H, t).

WO 01/44170 PCT/SE00/02505
28
e) 2-ChIoro-5-[3-[(methylsulfonyl)oxy]propylI-Ar-(tricyclo{33.1.1:5*7]dec-l-
ylmethyl)-benzamide
Methanesulfbnyl chloride (1.1ml) and triethylamine (2ml) were added to a solution of 2-chloro-5-(3-hydroxypropyl)-A'-(tricyclo[3.3.1.1I,7]dec-1 -ylmethyl)- benzamide (Example 6d, 2.65g) in dichloromethane at 0°C. After lh the reaction mixture was diluted with ethyl acetate and extracted once with water, twice with saturated sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced pressure to give the subtitled compound as an oil which slowly solidified (3.2g).
MS (APC1 +ve) 440/442 (M+H)+
'HNMR (CDC13) 5 7.55 (1H, d); 7.34 (1H, d); 7.20 (1H, dd); 6.32 (1H, t, br); 4.21 (2H, t);
3.18 (2H, d); 3.01 (3H, s); 2.77 (2H, t); 2.09 (2H, quin); 2.01 (3H, s); 1.69 (6H, q); 1.59
(6H,d).
f) 2-Chloro-5-[3-[(2-hydroxyetiiyl)aniinolpropyl]-iV-(tricyclo[33.1.13-7]dec-l-ylmethyl)-benzamidei acetate salt
Ethanolamine (0.07ml) was added to a suspension of 2-chloro-5-[3-[(methylsulfonyl)oxy]propyl]-iV-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide (Example 6e, 0.170g) in n-butanol (5ml) and heated at 100°C in a sealed tube for I2h. On cooling to ambient temperature the solution was diluted with ethyl acetate and extracted twice with
saturated aqueous sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced pressure. Purification by preparative reverse phase HPLC (eluting with a gradient of acetonitrile in 0.1% aqueous ammonium acetate /25-95%) gave the title compound as the acetate salt (0.070g).
MS (APCI+ve) 405/407 (M+H)+
JHNMR (DMSO-dJ 5 8.28 (1H, t); 7.36 (1H, d); 7.25 (1H, dd); 7.20 (1H, d); 3.44 (2H, t);
2.92 (2H, d); 2.50-2.65 (6H, m); 1.94 (3H, s); 1.87 (3H, s); 1.74-1.61 (8H, m); 1.52 (6H, s).

WO 01/44170

PCT/SEOO/02505

29
Example 7
2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyII-A^-(tricyclo[3J.l.l3'7]dec-l-yImethyl)-
benzamide, hydrochloride salt
H
,0H


3-AminopropanoI (1ml) was added to a solution of 2-chloro-5-[3-
10
[(methylsulfonyl)oxy]propyl]-N-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide (0.270g, Example 6e) in tetrahydrofuran (30ml) and the solution heated at reflux for 12h. On cooling fo ambient temperature the reaction'mixture was diluted with water and extracted thrice with dichloromethane. The organic extracts were combined, dried over magnesium sulfate and concentrated under reduced pressure. Purification by preparative reverse phase HPLC eluting with a gradient of acetonitrile / 0.1% aqueous ammonium acetate (25-95%), gave the title compound as the acetate salt Treatment with 4M hydrochloric acid in is dioxane gave the title compound as the hydrochloride salt (0.070g).

20

MS (APCI+ve) 419/421 (M+H)+
'H NMR (QMSO-ds) 6 8.67 (2H, s); 8.31 (1H, t); 7.41(1H, d); 7.30-7.25 (2H, m); 4.74 (1H, t); 3.47 (2H, q); 2.95-2.85 (6H, m); 2.67 (2H, t); 2.00-1.84 (5H, m); 1.76 (2H, quin); 1.63 (6H,q); 1.52 (6H,s).

Example 8
2^Woro-5-[3Kmethylammo)propyI]W^tricyclo[3J.l.l3'7]dec-l-ylmethyl)-benzamide, acetate salt

WO 01744170

PCT/SE00/02505

30




10

Methylamine (2M tetrahydrofuran, 8ml) was added to 2-chloro-5-[3-[(memylsuIfonyl)oxy]propyl]-/V-(tricycIo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide (0.250g, Example 6e) and heated in a sealed tube at 70°C for 18h. On cooling to ambient temperature, the solution was diluted with-ethyl acetate and extracted twice with saturated sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced' pressure. Purification by preparative reverse phase HPLC (eluting with a gradient of acetonitrile in 0.1% aqueous ammonium acetate /25-95%) gave the title compound as the acetate salt (0.140g).
MS (APCI +ve) 375/377 (M+H)+
"H'NMR"(DMS'6"-d6y'8 "8.36'(iH,"t); 7.37 (1H, d); 7.24 (1H, dd); 7.21 (1H, d); 2.92 (2H, d); 2.62 (2H, t); 2.53 (2H, t); 2.30 (3H, s); 1.94 (3H, s); 1.86 (3H, s); 1.57-1.77 (8H, m); 1.52 (6H,s).

15

WO 01/44170

PCT/SEOO/02505

31
Example 9
2-Chloro-5-[3-[(l-methylethyI)aminoJpropyl]-Ar-(tricyclo[33.1.13'7]dec-l-yImethyl)-
benzamide, hydrochloride salt




10

Isopropylamine (0.5ml) was addedlo a solution of 2-chloro-5-[3-[(methylsiilfonyOoxyjpropylj-A^^cyclop.S.l.l^'jdec-l-ylmemy^-berizamide^^SOg, Example 6e) in tetrahydroruran (20ml) and heated at 70°C in a sealed tube for 24h. The mixture was concentrated under reduced pressure and the residue purified by solid phase extraction on SCX resin. The title product was isolated as the hydrochloric acid salt (0.1 Og).



15

MS (APCI +ve) 403/405 (M+H)+
!H NMR (DMSO-d6) 5 8.67 (2H, s); 8.31 (IH, t); 7.41 (IH, d); 7.30 (IH, dd); 7.26 (IH, d); 3.33-3.22 (IH, m); 2.93 (2H, d); 2.87 (2H, s); 2.69 (2H, t); 1.86-1.95 (5H, m); 1.63 (6H, q); 1.52 (6H,s); 1.22 (6H,d).



20

Example 10
5-[3-[(2-Amino-2-methylpropyl)aniino]propyl]-2-chloro-iV-(tricyclo[3J.l.l3'7]dec-l-ylmethyl)-benzamide, dihydrochloride salt

WO 01/44170

PCT/SE00/02505

32




10

2-Mediyl-l,2-propanediamine (0.12ml) was added to a solution of 2-chloro-5-[3-[(methylsulfonyl)oxy]propyl]-JV-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide (0.250g, Example 6e) in tetrahydrofuran (4ml) and heated at 60°C in a sealed tube for 12h. On cooling to ambient temperature, the mixture was diluted with ethyl acetate and extracted twice with saturated sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced pressure.. Purification by preparative reverse phase HPLC (eluting witfi a gradient of acetonitrile in 0.1% aqueous ammonium acetate 125-95%) gave the title compound as the acetate salt Treatment with 4M hydrochloric acid in dioxane gave the title compound as the dihydrochloride salt (0.045g).



15

MS (APCI+ve) 432/434 (M+H)+
'H NMR (DMSO-d6) 5 9.40 (2H, m); 8.60 (3H, m); 8.32 (IH, t); 7.41 (IH, d); 7.31 (IH, d); 7.27 (IH, s); 3.20 (2H, s); 2.92 (4H, d); 2.71 (2H, t); 2.01 (2H, quin); 1.94 (3H, s); 1.6: (6H, q); 1.52 (6H, s); 1.39 (6H, s).



20

Example 11
2-Chloro-5"-[3-[(4>-hydroxybutyI)amino]propyl]-A'-(tricyclo[33.1.13'7]dec-l-ylmethy^-
benzamide

WO 01/44170
PCT/SE00/02505
33 H

H
&-' ..
4-Amino-l-butanol (0.11ml) was added to a solution of 2-chloro-5-[3-[(methylsulfonyl)oxy]propyl]-iV-(tricyclo[3.3.1.13,7]dec-l -ylmethyl)-benzamide (0.25g, Example 6e) in tetrahydrofuran (4ml) and heated at 60°C in a sealed tube for 12h. On s cooling to ambient temperature, the mixture was diluted with ethyl acetate and extracted twice with saturated aqueous sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced pressure. Purification by preparative reverse phase HPLC (eluting with a gradient of acetonitrile in 0.1% aqueous ammonium acetate /25-95%) gave the title compound as the acetate salt Treatment with io aqueous 2M sodium hydroxide and extraction into ethyl acetate gave the title compound (0.065g).
MS (APCI +ve) 433/435 (M+H)+
'H NMR (DMSO-d6) 5 8.28 (1H, t); 7.35 (1H, d); 7.24 (1H, dd); 720 (1H, d); 3.37 (2H, 15 t); 2.92 (2H, d); 2.63 (2H,.t); 2.40^2.60 (4H,m); 1.92 (3H, s); 1.70-1.55 (8H, m); 1.52 (6H, s); 1.40-1.45 (4H,m).
Example 12
2-ChJoro-5-[3-[(2-hydroxy-2-methyIpropyl)aininojpropyl]-AL(tricyclo[3J.l.l3'7]dec-l-20 ylmethy])-benzamide, acetate salt

WO 01/44170

PCT/SE00/Q2505

34
-M>


10

2-Hydroxy-2-methyl-1 -propylamine [prepared according to Journal American Chemical Society (1941), 63, pl034] (0.25ml) was added to a solution of 2-chloro-5-[3-[(methylsulfonyl)oxy]propyl]-7V-(tricyclo[3.3.1.13,7]dec-l -ylmethyl)-benzamide (0.250g, Example 6 e) in butan-1-ol (8ml) and heated at 100°C in a sealed tube for 24h. On cooling
to ambient temperature, the mixture was diluted with ethyl acetate and extracted twice with saturated aqueous sodium hydrogencarbonate solution and once with brine, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by solid phase extraction on SCX resin and preparative reverse phase HPLC (eluting with a
gradient of acetonitrile in 0.1 % aqueous ammonium acetate /25-95%) to give the title compound as the acetate salt (0.160g).



15

MS (APCI+ve) 433/435 (M+H)+
!H NMR (DMSO-ds) 5 8.29 (1H, t); 7.36 (1H, d); 7.26 (1H, d); 7.21 (1H, s); 2.92 (2H, d);
2.63 (2H, t); 2.55 (2H, t); 2.40 (2H, s); 1.94 (3H, s); 1.88 (3H, s); 1.80-1.58 (8H, m); 1.52
(6H,s);1.08(6H,s).

Example 13
2-ChIoro-5-[3-[[2-(methylammo)ethyI]amino]propyl]-Ar-(tricycIo[3J.l.l:5'7]dec-l-20 ylmethyO-benzamide, dihydrochloride salt

WO 01/44170

PCT/SEOO/02505

35



a) 2-ChIoro-5-(3-oxopropyl)-benzoic acid,
2-Chloro-5-iodobenzoic acid (5.0g), tetrabutylammonittm chloride (5.0g), sodium hydrogencarbonate (5.3g) and allyl alcohol (1.6ml) were combined in N,N-5 dimethylformamide (50ml) and PdCl2 (O.tfg) was added under nitrogen. After 24h ethyl acetate and 2M hydrochloric acid were added to the crude reaction mixture and the precipitated Pd filtered off. The organic phase was separated and washed thrice with 2M hydrochloric acid men once with brine and dried over magnesium sulfate, filtered and evaporate. Purification by chromatography on silica (eluting ethyl acetate : acetic acid / 10 19:1) gave the subtitled product as an oil (2.77g).

15
20

MS m/z 212/214
VH NMR (CDC13) 5 9.82 (1H, s); 7.83 (1H, d); 7.42 (1H, d); 7.30 (1H, dd); 2.98 (2H, t);
2.83 (2H,t). • '
b) 2-Chloro-5-[3-[{(l,l-aimethyletho3y)carbouyl][2-H(l,l-dimethylethoxy)carboayl]methylanuno]ethyl]amin.o]propyl]-beiizoicacid,
Sodium triacetoxyborohydride (31 Omg) was added to a solution of (2-aminoethyl)methyl-, 1,1 -dimethylethyl carbamic acid ester [prepared according to J.Med.Chem (1990), 33(1), 100] (0.156g) and 2-chloro-5-(3-oxopropyl)-benzoic acid (0.21g, Example 13a) in methanol (15ml). After 24h, acetic acid (0.2ml) was added and the mixture evaporated to dryness. The residue was redissolved in dichloromethane (10ml), triethylamine (0.45ml) and (1,1-dimethylethoxy)carbonyl 1,1-dimethylethyl

WO 01/44170

PCT/SE00/02505

36
Carbonic acid ester (Ig) was added. After 24h the reaction mixture was washed twice with 10% KHSO4, once with brine and dried over magnesium sulfate, filtered and evaporated.
Purification by chromatography on silica (eluting with iso-hexane : ethyl acetate: acetic acid / 80:20:1 then ethyl acetate : acetic acid / 100:1) gave the subtitled product as an oil
5 (0.2g).
MS (APCI+ve) 471/473 (M+H)+
c) 2-Chloro-5-[3-[[2-(methylamino)ethyl]aniino]propyL]-A'r- 10 PyBrOP(0.2g) was added to a solution of 2-chloro-5-[3-[[(l, 1-
dimethylethoxy)carbonyl] [2-[[(l, 1 ^imemylemoxy)carbonyl]methylamino]ethyl]-amino]propyl]-benzoic acid (0.2g, Example 13b), adamantanemethylamine (0.1ml) and ' triethylamine (0.15ml) in /V;2V-dimemylformamide (10ml). After lh the reaction mixture was diluted with ethyl acetate and washed with water, then washed twice with ammonium
is chloride solution, twice with saturated sodium hydrogencarbonate solution and once with brine. The organic extracts were dried over magnesium sulfate, filtered, evaporated and purified by chromatography on silica (eluting with dichloromethane": methanol /2-10%). The product was redissolved in dichloromethane : methanol /1:1 (15ml) and 4M hydrochloric acid in dioxane (2ml) added. The mixture was stirred until deprotection was 20 complete then purified by prep RP-HPLC (acetonitrile/0.1 % aqueous trifluoroacetic acid). Conversion to the hydrochloride salt by treatment with 4M hydrochloric acid in 1,4-dioxane/methanol gave the title compound (0.055g).
MS (APCI_.+ve) 418/420 (M+H)+ 25 !H NMR (DMSO-ds) 5 9.50-9.00 (4H, m); 7.42 (1H, d); 7.29 (1H, d); 7.27 (1H, s); 3.25 (4H, s, br); 3.05-2.90 (4H, m); 2.70 (2H, t); 2.60 (3H, s); 2.00-1.90 (5H, m); 1.63 (6H, q);
1.52 (6H,s). Example 14

WO 01/44170

PCT/SE00/02505

37
(S)-2-ChIoro-5^34(2-hydroxyprqpyI)araino]propyI]-Ar-(tricyclo(3J.l.l3'7ldec-l-ylmethyl)-benzamide, hydrochloride salt




10
15

a) 2^hloro-5-iodo-Ar-(tricycIo[3J.l.l3'7]dec-l-ylmethyl)-beii2ainide,
2-Chloro-5-iodobenzoic acid (lO.Og) was suspended in dichloromethane (160ml) then oxalyl chloride (4.0ml) was added followed by A^-dimethylformamide (40ul). After 24 h the solvent was evaporated to afford a white solid, which Was redissolved in dichloromethane (160ml). Triethylamine (14.8ml) was added followed by adamantyhnemylarnine (6.9ml) with cooling to maitain a temperature below 30°C. The resulting cloudy mixture was stirred for lh, then evaporated to give a pale yellow solid. This was stirred in a mixture of ethyl acetate (400ml) and 2M hydrochloric acid (300ml) until the solid dissolved to give 2 clear phases. The (upper) organic phase was separated and washed with 2M aqueous sodium hydroxide solution (300ml), then dried (Na^O,) and evaporated to a yellow solid. The solid was suspended in iso-hexane (100ml), then filtered and washed with more iso-hexane (40ml). The resulting off-white solid was dried in a vacuum oven at 40°C (14.0g).

MS (APCI+ve) 430/432 (M+H)+
20 'H NMR (CDC13) 8 8.00 (IH, d); 7.66 (IH, dd); 7.14 (IH, d); 6.17 (IH, s, br); 3.17 (2H, d); 2.01 (3H, s); 1.69 (6H, q); 1.58 (6H, d).
b) 2-CMoro-5-(3^xopropyI)-iV^tricy^

WO 01/44170

PCT/SE00/02505

" 38
2-Chloro-5-iodo-iV-(tricyc]o[3.3.1.13,7]dec-1 -ylmethyr)-benzamide (5.00g, Example 14a), tetrabutylammonium chloride (3.40g) and sodium hydrogencarbonate (2.44g) were charged to a flask. Pd(OAc)2 (0.0533g), toluene (50ml) and allyl alcohol (1.01ml) were added to afford a pale brown mixture which was heated at 80°C for 5h. The resulting dark 5 brown mixture was cooled to ambient then filtered to remove the solid residues. These were washed with further toluene (2 x50ml) and the combined toluene extracts then washed with water (100ml), dried over MgS04 and concentrated to a light brown solid
(3.82g).
10 MS (APCI+ve) 360/362 (M+H)+
!H NMR (CDC13) 8 9.81 (IH, s), 7.56 (IH, s); 7.32 (IH, d); 7.19 (IH, d); 6.28 (IH, s, br); 3.18 (2H, d); 2.96 (2H, t); 2.81 (2H, t); 2.01 (3H, s); 1.70 (6H, q); 1.58 (6H, s).
c) (S)-2-Chloro-5-[3-((2-hydroxypropy0amino]propyI]-A^(tricycIo{3J.l.l:5'7]dec-l-15 ylmethyl)-benzamide, hydrochloride salt
Sodium triacetoxyborohydride (0.6g) was added to a solution of 2-chloro-5-(3-oxopropyl)-7/-(tricyclo[3.3.1.13'7]dec-l-ylmethyl)-benzamide (0.5g, Example 14b) and (S> 2-hydroxypropylamine (0.3 lg) in dichloromethane (5ml). After 24h the crude reaction
mixture was purified by flash chromatography (eluting with 5-20% methanol in 20 dichloromethane + 1 % ammonia) and the hydrochloride salt precipitated from ether/methanol 19:1, to afford the tide compound as a white solid (0.19g).
MS (APCI+ve)419/421 (M+H)+
'H NMR (DMSO-d6) 5 8.70-8.40 (2H, d, br); 8.30 (lH,-t); 7.41 (IH, d); 7.28 (IH, dd); 7.24 25 (IH, d); 5.32 (IH, d); 3.97-3.90 (IH, m); 3.00-2.85 (5H, m); 2.75 (IH, t); 2.65 (2H, t);
2.Q0-1.90 (5H, m); 1.64 (6H, q); 1.52 (6H, s); 1.09 (3H, d).
Example 15
(RH^Woro-S-p-^-hydroxypropy^aminojpropylJ-iV-ttricycIolSJ.l.l^Jdec-l-30 yimethyQ-benzamide, hydrochloride salt

WO 01/44170

PCT/SEOO/02505

39

Prepared according to the method described for Example 14.
5 MS(APCI+ve)419/421.(M+H)+
lH NMR (DMSO-ds) 5 8.70-8.40 (2H, d, br); 8.30 (IH, t); 7.41 (IH, d); 7.28 (IH, dd); 7.24 (IH, d); 5.32 (IH, d); 3.97-3.90 (IH, m); 3.00-2.85 (5H, m); 2.75 (IH, t); 2.65 (2H, t); 2.00-1.90 (5H, m); 1.64 (6H, q); 1.52 (6H, s); 1.09 (3H,d).
10 Example 16
15 Prepared according to the method described for Example 14.
(R)-2<:hloro-5- hydrochloride salt>

WO 01/44170

PCT/SEOO/02505

40
MS (APCI +ve) 419/421 (M+H)+
'H NMR (DMSO-d6) 8 8.80-8.40 (2H, d, br); 8.31 (IH, t); 7.42 (IH, d); 7.28 (IH, dd); 7.25 (IH, d); 5.36 (IH, s); 3.65-3.60 (IH, d, br); 3.55-3.45 (IH, m); 3.25-3.15 (IH, m); 2.95-2.85 (4H, m); 2.65 (2H, t); 2.00-1.90 (5H, m); 1.63 (6H, q); 1.52 (6H, s); 1.20 (3H,d).
Example 17
2-Chloro-5-{3-[[2-hydroiy-l-(hydroxymethyl)-l-methyIethyI]aminolpropyl]-A^-(tricy do [3 3.1.13'7] dec-l-ylmethyL)-benzamide

Prepared according to the method described for Example 14.
MS (APCI +ve) 449/451 (M+H)+
'H NMR (DMSO-ds) § 8.27 (IH, t); 7.36 (IH, d); 7.24 (IH, dd); 7.21 (IH, d); 4.32 (2H, s);. 3.22 (4H, s); 2.92 (2H,.d); 2.65-(2H, t); 2.45 (2H, q(on edge of DMSO)); 1.92 (3H, s); 1.70-1.57 (8H, m); 1.52 (6H, s); 0.85 (3H,s).
Example 18 5-[3-[[2-(Acetylammo)ethyl]ainmo]propyI]-2-cIdoro-iV-(tricycIo[33.1.13>7]dec-l-
ylmethyQ-benzamide, hydrochloride salt

WO 01/44170

PCT/SE00/02505

41

Prepared according to the method described for Example 14.
MS (APCI +ve) 446/448 (M+H)+
'H NMR (DMSO-d6) 5 8.90 (2H, s, br); £32 (IH, t); 8.22 (IH, t); 7.41 (IH, d); 7.28 (IH, dd); 7.24 (IH, d); 3.33 (2H, q); 2.95-2.85 (6H, m); 2.63 (2H, t); 2.00-1.86 (5H, m); 1.84 (3H, s); 1.63 (6H, q); 1.52 (6H, s).
Example 19
icyaied according to the method described for Example 14.
MS (APCI +ve) 460/462 (M+H)+
2<:uoro-5- dihydrochloride salt>

WO 01/44170

PCT/SE00/02505

42
'H NMR (DMSO-dJ 8 10.70 (IH, s); 9.48 (2H, s); 8.31 (IH, t); 7.42 (IH, d); 7.30 (lH, dd); 7.27 (IH, d); 3.50-3.30 (2H, m); 3.25-3.10 (4H, m); 3.00-2.90 (4H, d, br); 2.71 (2H, t); 2.00-1.90 (5H, m); 1.63 (6H, q); 1.52 (6H, s); 1.24 (6H, t).
s Example 20
2-CUoro-5-[3-{(3-methoiypfopyl)amino]propyl]-7V'-(tricyclo[3.3.1.1:5,7]dec-l-ylmethyl)-benzamide, hydrochloride salt

Prepared according to the method described for Example 14.
MS (APCI +ve) 433/435 (M+H)+
[H NMR (DMSO-dfi) 8 8.77 (2H, s, br); 8.31 (IH, t); 7.41 (IH, d); 7.28 (IH, dd); 7.25 (IH,
d); 3.40 (2H, t); 3.23 (3H, s); 3.00-2.75 (6H, m); 2.67 (2H, t); 2.00-1.80 (7H, m); 1.63 (6H,
q);L52(6H,s).
Example 21 2-CUoro-5-[3-[(3-hydroxy-3-methyIbutyl)amino]propyl]-iV-(tricyclo[33.1.13'7]dec-l-
ylmethyl)-benzamlde, hydrochloride salt

WO 01/44170

PCT/SE00/02505

43



Prepared according to the method described for Example 14.
MS(APCI+ve)(M+H)+ 5 'H NMR (DMSO-d6) 5 8.57 (2H, s, br); 8,30 (IH, t); 7.42 (IH, d); 7.29 (IH, dd); 7.25 (IH, d); 4.61 (IH, s); 3.05-2.85 (6H, m); 2.64 (2H, t); 2.00-1.82 (5H, m); 1.73-1.53 (8H, m); 1.52 (6H,s); 1.12 (6H,s).
Example 22 io 2-CUoro-5-[3-[(2-methoxyethyl)amino]propyl]-Ar-(tricyclo[3J.l.l3,7]dec-l-ylmethyl)-benzamide, hydrochloride salt




15

Prepared according to the method described for Example 14.
mp 245-248 °C
MS (APCI +ve) 419/421 (M+H)+

WO 01/44170

PCT/SEOO/02505

44
'H NMR PMSO-d6) 5 8.79 (2H, s); 8.30 (1H, t); 7.41 (lH,.d); 7.27 (1H, dd); 7.25 (1H, d); 3.58 (2H, t); 3.30 (3H, s); 3.09 (2H, s, br); 2.95-2.85 (4H, m); 2.67 (2H, t); 1.95-1.86 (5H, m); 1.63 (6H,q); 1.52 (6H,s).
5 Example 23
2-Chloro-5-[[3-(methylamino)propory]methyl]-Ar-(tricyclo[3J3.1.13'7]dec-l-yImethyl)
benzamlde



10
a) 2-Chloro-5-[[3-[[(l,l-dimethylethpxy)carbonyl]methyIainino]propoxy]methyl]-benzoicacid
15
(3-Hydroxypropyl)methyl-carbamic acid, 1,1-dimethylethyl ester (0.272 g) in tetrahydrofuran (5 ml) was cooled to 0°C under nitrogen. Sodium hydride (60% dispersion in oil, 0.110 g) was added. The mixture was allowed to warm to room temperature and stirred for 30 min. 5-(Bromomethyl)-2-chloro-benzoic acid (0.300 g) in tetrahydrofuran (3 ml) was added and the mixture heated at 55°C for 6h. The solution was cooled, poured into saturated aqueous potassium hydrogensulfate solution, extracted into ethyl acetate (x 3), dried over magnesium sulfate, filtered and concentrated under reduced pressure to afford
the subtitled compound (0.431 g). 20 MS(ESI+ve)358(M+H)+ (ESI-ve) 356 (M-H)+
b) [3-[[4^Moro-3-U(tricyclo[33.1.13*7]dec-l-ylmetfayI)aniino]carbonyl]pheiiyl]-methoxylpropyl]methyl-carbamic acid, 1,1-dimethylethyl ester

WO 01/44170

PCT/SEOO/02505

45
2-Chloro-5-[[3-[[(l, l-dimemylemoxy)carbonyl]methyIamino]propoxy]methylj-
benzoic acid (0.318 g, Example 23a), carbonyl diimidazole (0.165 g) and
dimethylformamide (10 ml) were heated at 50°C under nitrogen for 30 min. The mixture was allowed to cool to room temperature and 1 -adamantanemethylamine (0.18 ml) was added. The mixture was stirred at room temperature for 20h then poured into ethyl acetate and washed with saturated aqueous sodium hydrogencarbonate solution followed by brine. The solution was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel (eluting with 2:1 isohexane/ethyl acetate) to afford the subtitled compound (0.236 g). MS (ESI +ve) 505 (M+H)+
c) 2-Chloro-5-[[3-(methylamino)propoxy]methyI]-A^-(tricyclo[33.1.13'7]dec-l-yhnethyl)-benzamide
[3-[[4-Chloro-3-[[(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)amino]carbonyl]phenyl]-methoxy]propyl]methyl-carbamic acid, 1,1-dimethylethyl ester (0.236 g, Example 23b), 4M hydrogen chloride in 1,4-dioxane (5 ml)' and methanol (5 ml) were stirred together under nitrogen for 3h, then poured into 25% aqueous ammonia solution and concentrated under reduced pressure to give the free base. This was purified by column chromatography over silica gel^ eluting with 19:1:0.1 / dichloromethane:methanol: ammonia to afford the tide compound as an oil CO. 106 g).
MS (APCI +ve) 405/407 (M+H)+
]H NMR (CDClj) 5 7.64 (1H, s); 7.39-7.33 (2H, m); 6.29 (1H, t, br); 4.49 (2H, s); 3.55 (2H, t); 3.18-3.17 (2H, d); 2.72-2.68 (2H, t); 2.44 (3H, s); 2.01 (3H, s, br); 1.86-1.79 (2H, m); 1.75-1.63 (6H,m); 1.59 (6H,s).
Example 24
2<:moro-5-h2- ylmethyl acetic acid salt>
WO 01/44170

PCT/SEOO/02505

46

37
a) 5-(BromomethyI)-2-chloro-N-(2-tricyclo[3-3.1.1 ' ]dec-l-ylmethyl)-benzamlde
To a solution of 2-chloro-5-(bromomethyl)-benzoic acid (1.0 g) in dichloromethane (25ml) at 0°C was added dimemylfonnamide (0.05ml) followed by oxalyl chloride (0.52 ml). The reaction was allowed to warm to room temperature and stirred for 30min. The volatiles were removed under vacuum and the residue dried under high vacuum. The residue was dissolved in dichloromethane (20 ml) and added to a solution of 2-adamantanemethylamine hydrochloride salt (0.95g) in dichloromethane (20ml) and diisopropylemylamine (2 ml) at 0°C. The reaction was allowed to warm to room temperature and stirred for 2h. The organics were washed with water (20ml) then saturated aqueous ammonium chloride solution and the organic layer dried over magnesium sulfate ftenjfiltered. The filtrate was concentrated under reduced pressure to a solid. The. crude material was recrystallised from dichloromethane/hexane to afford the subtitled compound as a white solid (1.3 g).
b) [2-[[4-CbJoroO-[[(tricyclo[33.1J3,7]dec-l-ylmethyl)amino]carbonyl]phenyIJ-
methoxy] ethyl] (2-hydroxyethyl)-carbamic acid, 1,1-dimethyIethyl ester
3 7 A mixture of 5-(bromomethyl)-2-chloro-N-(2-tricyclo[3.3.1.1 * Jdec-1-ylmethyl)-
benzamide (Example 24a, 0.300g), bis(2-hydroxyethyl)-carbamic acid, 1,1-dimethylethyl ester (0.312g) and silver trifluoroacetate (0.336 g) in dichloromethane (30 ml) was-stirred
under nitrogen at room temperature for 20h. The solution was then decanted from the silver salts and the dichloromethane removed under vacuum. The crude material was purified on silica gel (eluting with ethyl acetate) to afford the subtitled compound as an oil (0.249g).

WO 01/44170
47
MS (ESI +ve) MW 521/523 (M+H)+
c) 2-Chloro-5-[[2-[(2-hydroxyethyl)amino]ethoxy]methyI}-iV'-(tricyclo[33.1.13-7]dec-s l-ylmethyl)-ben2amide, acetic acid salt
[2-[[4-CWoro-3-[[(tricyclo[3.3.1.13'7]dec-l-ylmethyl)amino]carbonyl]phenyl]-methoxy]ethyl](2-hydroxyediyl)-carbamic acid, 1,1-dimethyleuiyl ester (0.286 g, Example 23b), 4M hydrogen chloride in 1,4-dioxane (10 ml) and methanol (10 ml) were stirred together under nitrogen for 20h, poured into 25% aqueous ammonia solution and 10 concentrated under reduced pressure to give the free base. This was purified by column chromatography over silica gel, eluting with 19:1:0.1 / dichloromethane:methanol: ammonia and further purified by reverse-phase hplc (75:25 to 5:95 / 0.1% aqueous ammonium acetate:acetonitrile) to afford the title compound as an oil (0.051 g).
is MS(APCI+ve)421/423(M+H)+
JH NMR (CDC13) 5 7.66 (1H, d); 7.38 (1H, d); 7.31 (1H dd); 6.68 (1H, t, br); 4.52 (2H, s); 3.72 (2H, t); 3.63 (2H, t); 3.17 (2H, d); 2.95 (2H,"t); 2.85 (2H, t); 2.01 (3H, s, br); 1.91 (2H, s); 1.75-1,63 20 Example 25
2-Chloro-5-[[2-[(3-hydroxypropyl)amino]ethoxy]methyl]-iV^(tricyclo[3-3.1-l3'7]dec-l-ylmethyl)-benzamide, acetic acid salt


WO 01/44170

PCT/SE00/02505

48
a) 2-C]lloro-5-[(2-hydroxyethoxy)methyIj-iV-(tricycIo[3J.I.l3'7]dec-l-yIinethyl)-
benzamide
3 7
A mixture of 5-(bromomethyI)-2-chloro-N-(2-tricyclo[3.3.1.1 ' ]dec-1-ylmethyl)-benzamide (Example 24a, 0.300g), ethylene glycol (0.094g) and silver trifraoroacetate 5 (0.336 g) in dichloromethane (10 ml) was stirred under nitrogen at room temperature for 20h. The solution was then decanted from the silver salts and the dichloromethane removed under vacuum. The crude material was purified on silica (eluting with ethyl acetate) to afford the subtitled compound as an oil (0.228g).
io MS (ESI +ve) MW 378/380 (M+H)+
b) 2-Chloro-5-[[2-[(methylsulfonyl)oxy]ethoxy]methy!]-iV-(tricyclo[33.1.13'7ldec-l-ylmethyl)-benzamide
2-CWoro-5-[(2-hydroxyemoxy)me&yl]-AT-(tricyclo[3.3.1.13-7]dec-l -ylmethyl)-15 benzamide (0.228 g, Example 25a) and triethylamine (0.21 ml) in dichloromethane (10 ml) were cooled to 5°C under nitrogen and methanesulfonyl chloride (0.1 ml) was added. The mixture was stirred at room temperature for 20h then poured into 2N hydrochloric acid, and extracted into ethyl acetate. The combined extracts were washed with 2N
hydrochloric acid, saturated aqueous sodium hydrogencarbonate solution then brine, and 20 dried over magnesium sulfate. The organics were filtered and concentrated under reduced pressure to afford the subtitled compound as a white solid (0.160 g), !
*H NMR (CDClj) 5 7.66 (1H, s); 7.41-7.33 (2H, m); 6.32 (1H, t, br); 4.57 (2H, s); 4.40-4.38 (2H, m); 3.77-3.75 (2H, m); 3.17-3.15 (2H, d); 3.04.(3H, s); 2.01 (3H, s, br); 1.75-25 1.64 (6H, m); 1.59 (6H, s, br).
c) 2-CWoro-5-[[2-[(3-hydroxypropyl)aminoJethoxy]methyJl-iV'-.
(tricydo[33.1.13,7]dec-l-ylmethyI)-beiizamide, acetic acid salt
2-CUoro-5-[[2-[(memylsmfonyl)oxy]ethoxy]methyl]-^-(tricyclo[3.3.1. l3,7]dec-1 -
30 ylmethyl)-benzamide (0.160 g, Example 25b),.3-amino-l-propanol (0.27 ml) and n-butanol

WO 01/44170

PCT/SE00/02505

50
(3.36g) and A^AW/isopropylemylarnine (5.55 ml) in dichloromethane (20 ml). The resulting solution was allowed to stir at room temperature under a nitrogen atmosphere for 20h. The reaction mixture was diluted with dichloromethane and washed in sequence with
r
water, 10% aqueous potassium carbonate solution, 10% aqueous potassium hydrogen 5 sulfate and saturated brine. The organic phase was then dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the subtitled compound as a solid (7.84
g).
MS (APCI +ve) 383/385 (M+H)+ io !H NMR (DMSO-d6) 5 8.42 (1H, t); 7.63 (1H, dd); 7.57 (1H, m); 7.45 (1H, d), 2.93 (2H,
d); 1.94 (3H, s, br); 1.69-1.58 (6H, m); 1.51 (6H, s).
b) 2-Chloro-5-formyl-iV-(tricyclo [33.1.13,7] dec-l-ylmethyl)-benzamide
A solution of 5-bromo-2-chloro-A^-(tricyclo[3.3.1.13'7]dec-l-ylmemyI)-benzarnide 15 (3.25 g, Example 25a) in tetrahydrofuran (150 ml) was cooled to -78?C under a nitrogen atmosphere. A solution of 1.4M methyllithium in diethyl ether (6.1 ml) was added to this solution over 2min. The mixture was stirred at -78°C for lOmin, then a 1,7M solution of ter^butyllithium in pentane (10.0 ml) was added dropwise. The mixture was stirred at -78°C for a further 10 min, then dimethylfonnamide (1.0 ml) was added. The resulting 20 solution was stirred at -78°C for 30 mim quenched with saturated aqueous ammonium chloride solution (100 ml) and extracted with ethyl acetate. The combined extracts were dried over sodium sulfate, filtered, and the filtrate concentrated under reduced pressure to give the subtitled compound as a solid (2.76 g).
25 MS (APCI +ve) 332/334 (M+H)+
'H NMR (DMSO-ds) 8 10.04 (1H, s); 8.49 (1H, t); 7.96-7.91 (2H, m); 7.74 (1H, d); 2.96 (2H, d), 1.95 (3H, s); 1.64 (6H, m); 1.53 (6H, d).
c) 2-CUoro-5-[[[3-[(l-methylethyI)ainino]propyl]amino]methyII-iV-30 (tricyclo[33.1.1i7]dec-l-yImethyI)-benzamide

WO 01/44170

PCT/SEOO/02505

51

10
15

A mixture of 2-chloro-5-formyl-Ar-(tricyclo [3.3.1.13,7ldec-l-ylmethyl)-benzamide (0.244 g, Example 25b), iV-isopropyl-l,3-propanediamine (0.211 g), p-toluenesulfonic acid (0.005 g) and toluene (30 ml) were refluxed together under Dean-Stark conditions for 3h. The mixture was cooled and concentrated under reduced pressure to an oil. This was
dissolved in ethanol (30 ml) and cooled to 0°C under a nitrogen atmosphere. Solid sodium borohydride ( 0.040 g) was added portionwise and the mixture stirred at room temperature for 30 min, men concentrated under reduced pressure and the residue purified by column chromatography over silica (eluting with 9:1:0.1 dichloromethane/ methanol/ 35% aqueous ammonia) to give the title compound (0.015 g) and a by-product (see Example 27).
MS (APCI +ve) 432/434 (M+H)+
lH NMR (CDC13) 5 7.64 (1H, s); 7.37-7.32 (2H, m); 6.28 (1H s, br); 3.78 (2H, s); 3.18 (2H, d); 2.84-2.74 (1H, m); 2.70-2.64 (4H, m); 2.01 (3H, s, br); 1.76-1.63 (8H, m); 1.59 (6H,s,br); 1.05 (6H,d).
Example 27
5-[[(3-AinmopropyI)ammo]methyl]-2-chJoro-Ar-(tricyclo[3JJJ3'7]dec-l-ylmethyl)-benzamide


NH,
20

Formed as a by-product in Example 26c above (0.125 g).
MS (APCI +ve) 390/392 (M+H)+

WO 01/44170

PCT/SEOO/02505

52
*HNMR (CDCI3) 5 7.65 (1H, s); 7.37-7.32 (2H, m); 6.31 (1H, t, br); 3.79 (2H, s); 3.18 (2H, d); 2.77 (2H, t); 2.68 (2H, t); 2.01 (3H, s, br); 1.75-1.61 (8H, m); 1.59 (6H, s, br).
Example 28 5 2-CbJoro-5-[[[2-[(l-methylethyl)amino]ethyl]amino]methyl]-Ar-(tricyclo[3J3.1.13'7]dec-l-ylmethyl)-benzamide



Synthesised as in Example 26 using 2-chloro-5-fonnyl-iV-(tricyclo [3.3.LI3,7] dec-1-io ylmethyl)-benzamide (0.500 g, Example 25b) and iV-isopropylethylenediamine (0.186 g) to give the title compound as a solid (0.105 g).

15

MS (APCI +ve) 418/420 (M+H)+
'H NMR (CDC13) 6 7.65 (1H, s); 7.34 (2H, s); 6.26 (1H, t, br); 3.79 (2H, s); 3.18 (2H, d); 2.79-2.69 (5H, m); 2.01 (3H, s, br); 1.75-1.64 (6H, m); 1.59 (6H, s, br); 1.50 (2H, s, br), 1.05 (6H,d).

Example 29
3-{[3-[4-Chloro-3-[[(tricyclo[33.1.13'7]dec-l-ylmethyl)amino]carbonyl]phenyl]-20 propyl]amino]prppanoic acid, 2,2-dimethylpropyl ester, trifluoroacetic acid salt

WO 01/44170

PCT/SE00/02505

53
Y a) 2-Chloro-5-iodo-7V-(tricyclo[3.3.1.13,7]dec-l-yImethyI)-benzamide
2-Chloro-5-iodpbenzoic acid (10.Og) was suspended in dichloromethane (160ml) then oxalyl chloride (4.0ml) was added followed by AW-dimemylformamide (40u.l). After 24 h the solvent was evaporated to afford a white solid, which was then redissolved in dichloromethane (160ml). Triethylamine-(14.8ml) was added, followed by adamantane methylamine (6.9ml) with cooling to keep the temperature below 30°C. The resulting slightly cloudy mixture was stirred for lh, then solvent was evaporated to give a pale yellow solid. The solid was stirred in a mixture of ethyl acetate (400ml) and 2M hydrochloric acid (300ml) until the solid dissolved to afford two clear phases. The (upper) organic phase was separated off and washed with 2M sodium hydroxide solution (300ml), then dried (Na,SO+) and evaporated to a yellow solid. The solid was suspended in iso-hexane (100ml), then filtered and washed with more iso-hexane (40ml), and the resulting off-white solid dried in vacuo at 40°C to afford the subtitled compound (14.0g).
MS (APCI +ve) 430/432 (M+H)+
'H NMR (CDClj) 8 8,00 (1H, d); 7.66 (1H, dd);.7.14 (1H, d); 6.17 (1H, s, br); 3.17 (2H, d);
2.01 (3H, s); 1.69 (6H, q); 1.58 (6H, d).
b) 2-Chioro-5-(3-oxopropyI)-A/'-(tricycIo[3J.l.l:i'7]dec-l-ylmethyI)-ben2amide,
2-Chloro-5-iodo-iV-(tricyclo(3.3.1.13,7]dec-1 -ylmemyl)-benzamide (5.00g Example 29a), tetrabutylammonium chloride (3.40g) and sodium hydrogencarbonate (2.44g) were charged to a flask, followed by Pd(OAc)2 (53.3mg), toluene (50ml) and allyl alcohol (1.01ml). The pale brown mixture was heated at 80°C for 5h, then cooled to ambient

WO 01/44170

PCT/SE00/02505

54
temperature. The mixture was filtered and the residues washed with additional toluene ■ (50ml+50ml). The combined toluene solutions were washed with water (100ml),then dried over MgS04 and evaporated to a light brown solid (3.82g).
MS (APCI +ve) 360/362 (M+H)+
'H NMR (CDC13) 5 9.81 (1H, s), 7.56 (1H, s); 7.32 (1H, d); 7.19 (IH, d); 6.28 (IH, s, br);
3.18 (2K, d); 2.96 (2H, t); 2.81 (2H, t); 2.01 (3H, s); 1.70 (6H, q); 1.58 (6H, s).
c) Z-Chloro-S-p-fCS-hydroxypropy^aminoJpropylJ-AKtricyclopj.l.l^'jdec-l-ylmethyl)-benzamide
Sodium triacetoxyborohydride (1.86g) was added to a solution of 2-chloro-5-(3-oxopropyl)-7yr-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-benzamide (1.57g, Example 29b) and 3-amino-l-propanol (0.8 ml) in dichloromethane (150ml). After 24h the crude reaction mixture was purified by chromatography (ehiting with 5-20% methanol in dichloromethane + 1 % ammonia) to give the subtitled compound as a white solid (1.05g).
MS (APCI +ve) 419/421 (M+H)+
d) 3-[[3-[4-Chloro-3-l[(tricycIo[3.3.1.13'7]dec-l-yImetfayI)amino]carbonyI]-phenyl]propyl][(14-dimethylethoxy)carbonyI]amino]propanoic acid, 2,2-dimethylpropyl ester
2-Cnloro-5-[3-[(3-hydroxypropyl)amino]propyl]-iV-(tricyclo[3.3.1.13,7]dec-1 -ylmethyl)-benzamide (0.271 g, Example 29c), iViiV-diisopropylethylamine (0.50 ml) and tetrahydrofuran (10 ml) were strirred together under nitrogen. Trimethylacetyl chloride (0.26 ml) was added dropwise and the mixture stirred at room temperature for 48h, then poured into water and extracted into ethyl acetate. The combined extracts were dried over
sodium sulfate, filtered, concentrated under reduced pressure and chromatographed over silica (eluting wim 4:1 isohexane/ethyl acetate) to give the subtitled compound (0.158 g) as an oil. .

WO 01/44170

PCT/SE00/02505

55
MS (ESI+ve) 603/605 (M+H)+
e) 3-[[3-[4-ChIoro-3-[[(tricyclo[3J.l.l3,7]dec-l-yImethyI)aminoJcarbonyII-phenyI]propyI]amino]propanoic acid, 2,2-dimethylpropyl ester, trifluoroacetic acid salt
3-[[3-[4-Chloro-3-[[(tricyclo[3.3.1.13-7]dec-l-yImethyl)amino]carbonyl]-phenyl]propyl][( 1,1 -dimethylethoxy)carbonyl]amino]propanoic acid, 2,2-dimethylpropyl ester (0.158 g, Example 29d), trifluoroacetic acid (2 ml) and dichloromethane (2 ml) were stirred together under nitrogen for 15 min, then concentrated under reduced pressure to give the title compound (0.170 g).
MS (APCI+ve) 503/505 (M+H)+
'H NMR (CDCy 5 7.40 (1H, d); 7.32 (1H, d); 7.14 (1H dd); 4.12 (2H, t); 3.16 (2H, d);
3.09-2.89 (4H, m); 2.64 (2H, t); 2.06-1.92 (7H, m); 1.75-1.63 (6H, m); 1.58 (6H, s); 1.18
(9H,s).
Example 30 5-(2-AiiiLmoethyI)-2-chloro-N-(tricycIo[3J.l.l:5'7]dec-l-yImethyl)beii2aniide

a) 2-CUoro-5-(cyanometiiyl)-7V^tricyclo[331.1l7ldec-l-ylmethyQben2aniide
Potassium cyanide (525mg) and 18-crown-6 (150mg) were added to a solution of 5-(>romomemyI>2-cWoro-N^2-tri
WO 01/44170 PCT/SEOO/02505
reaction mixture was evaporated to dryness and the residue partitioned between ethyl • acetate and saturated sodium hydrogencarbonate solution. The organics were separated, washed with brine, dried over magnesium sulfate, filtered and evaporated. Purification by chromatography on silica (eluting with a gradient of iso-hexane/ethyl acetate /4:I to 6:4) gave the subtitled product as a pink solid (1 .Og).
MS (APCI +ve) 343/345 (M+H)+
'HNMR (DMSO-dJ 5 8.38 (1H, t); 7.52 (1H, d); 7.43-7.38 (2H, m); 4.08 (2H, s); 2.94
(2H, d); 1.92 (3H, s); 1.63 (6H, q); 1.52 (6H, s).
b) [2-[4-Chloro-3-[[(tricycIo[33.1.13'7]dec-l-yImethyl)amino]carbonyI]phenyI]-ethyl] carbamic acid, 1,1-dimethyIethyI ester
Sodium borohydride (1.6g) was added portionwise to a cooled solution of 2-chloro-5-(cyanometiiyl)-A^((ricyclo[3.3.1.13'7]dec-l-yImethyl)benzamide (Example 30a, 2.1g),
(1,1 -dimethylethoxy)carbonyl carbonic acid, 1,1 -dimethylethyl ester (2.67g) and
cobalt(II)chloride (1.6g) in methanol (100ml). After 1.5h the solvent was evaporated and the residue slurried between ethyl acetate and saturated sodium hydrogencarbonate solution and the insoluble.cobalt salts-filtered. The organic phase was separated and washed with
brine, dried over sodium sulfate, filtered and evaporated to give the subtitled product as a foam(2.2g).
MS (APd +ve) 447/449 (M+H)+
'H NMR (CDC13) 5 7.54 (1H, d); 7.34 (1H, d); 7.19 (1H, dd); 6.28 (1H, s, br); 4.54 (1H, s,
br); 3.39 (2H3 q); 3.18 (2H, d); 2.80 (2H, t); 2.04 (3H, s); 1.70 (6H, q); 1.64 (6H, s); 1.42
(9H,s).
c) 5-(2-Ammoethyl)-2^bJoro-N-(tricycloI33J.l3'7]dec-l-yImethyl)benzamide, hydrochloride salt
Hydrochloric add (4M in 1,4-dioxane, 3.0ml) was added to a solution of [2-[4-chloro-3-[[(tricyclo[3.3.1.13'7]dec-l-yhnemyl)animo]carbonyl]phenyl]emyl]caroamicacid,

WO 01/44170

PCT/SE00/02505

57
1,1-dimethylethyl ester (2.2g, Example 30b) in methanol/dichlorometfaane (1:1) (50ml). After 24h the solvent was evaporated to leave the title compound as a foam (1.85g).
MS (APCI +ve) 347/349 (M+H)+
'H NMR (DMSO-d.) 8 8.31 (1H, t); 8.15 (3H, s, br); 7.43 (1H, d); 7.31 (2H, m); 3.05-2.98
(2H, m); 2.95-2.85 (4H, m); 1.94 (3H, s); 1.63 (6H, q); 1.52 (6H, s).

Example 31
Z-CMoro-S-p-ICa-hydroxyethyOpentylaminoJpropylJ-NKtricyclopJ.l.l^Jdec-l-
ylmethyl) benzamide
¥\J
H
Q 01
Prepared according to the procedure described in Example 6f MS (APCI +ve) 475/477 (M+H)+

WO 01/44170

PCT/SEOO/02505

58

Example 32
2-ChIoro-5-[3-(methyI-2-propenylamino)propyl]-N-(tricyclo[33.1.13*7]dec-l-
ylmethyl)- benzamide
P
N —
CI
/
Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 415/417 (M+H)+

Example 33
2-Chloro-5-{3-[[2-(dJmethyIamino)ethyl]methyIaminoIpropyI]-N-(tricycIo[3-3.1.13'7] dec-1-ylmethyl)- benzamide
—-N
O

WO 01/44170 PCT/SEOO/02505
59
Prepared according to the procedure described in Example 6f.
MS (APCI+ve) 446/448 (M+H)+
5 Example 34
5-{3-(Butylethylamjmo)propyI]-2-cfaIoro-N-(tricycIo[33.1.13'7Idec-l-yiinethyI)-benzamide

10
Prepared according to the procedure described in Example 6f. MS (APCI +ve) 445/447 (M+H)+

WO 01/44170

PCT/SE00/02505

60

Example 35
2-ChIoro-5-[3-(methyIpentylamino)propyI]-N-(tricycIo[33.1.13'7]dec-l-ylmethyI)-
benzamide
0
N—
b-MV

Prepared according to the procedure described in 6f MS (APCI +ve) 445/447 (M+H)+
Example 36 IO 2-ChIoro-5-[3-[[2-(diethylamino)ethyl]ethyIamino]propyI]-N-(tricycIo[33.1.1:5,7]dec-l-yhnethyl)- benzamide


WO 01/44170 PCT/SEOO/02505
61
Prepared according to the procedure described in Example 6f. MS (APCI +ve) 488/490 (M+H)+
5 Example 37
2-Chloro-5-[3-[(2-hydroxyethyl)methylamino]propyII-N-(tricycIo[3J.l.l;,'7]dec-l-ylmethyl)- benzamide

N~
" HO
10
Prepared according to the procedure described in Example 6f. MS (APCI +ve) 419/421 (M+H)+
15 Example 38
2-CUoro-5-[3-(dipropylamino)propyl]-N-(tricyclo[33.1.13,7]dec-l-ylmethyl)-benzamide

WO 01/44170

PCT/SE00/02505

62
^■^
Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 445/447 (M+H)+

Example 39
2-Chloro-5-[3-[(2-hydroxyethyI)(l-metliyIetIiyI)amino]propyI]-]Nf-
(tricyclo[3J.l.lJ,7Idec-l-ylmethyI)-benzamide
O
CI

10
Prepared according to the procedure described in Example 6f.
MS (APCI+ve) 447/449 (M+H)+
15 Example 40

WO 01/44170

PCT/SEOO/02505

63
5-[3-[Buty](2-hydroxyetfayl)amiiio]propyl]-2-chloro-N-{tricycIo[3J.l.l3'7]dec-l-ylmerltyl)-benzamide


w> .

Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 461/463(M+H)
10 Example 41
2-ChIoro-5-[3-(diethylamino)propyIJ-N^tricyclo[3J.lA3'7]dec-l-yIinethyl)-ben2amide

15 .Prepared according to the procedure described in Example 6£

WO 01/44170 PCT/SEOO/02505
64
MS(APCI+ve) 417/419(M+H)+
Example 42
2-Chloro-5-[3^dimethylamino)propyI]-N-(tricycJo[3J.l.l3,7]dec-l-yImethyl)-5 benzamide

Prepared according to the procedure described in Example 6t
10
MS(APCI+ve) 389/391 (M+H)+
Example 43
5-[3-{Butylmethylamino)propyl]-2-cWoro-N-(tricydo(3JJJ3'7]dec-l-yImethyI)-15 benzamide

WO 01/44170

PCT/SE00/02505

65



Prepared according to the procedure described in Example 6f.
5 MS (APCI +ve) 431/433(M+H)+
Example 44
2-Chloro-5-[3-[(2-hydroxyethyl)propylamino]propyl]-N-(tricyclo[33.1.13'7]dec-l-
ylmethyl)-benzamide
10


H-'

Prepared according to the procedure described in Example 6f.
is MS (APCI +ve) 447/449(M+H)+

WO 01/44170

PCT/SEOO/02505

66

Example 45 2-Chloro-5-[3-[ethyl(2-hydroxyethyI)amino]propyI]-N-{tricycIo{3J.l.l3'7]dec-l-
ylmethyl)-benzamide
tv>^
o
Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 433/435(M+H)+

10 Example 46
2-Chloro-5-[3-(dibutylainmo)propyI]-N-(tricyclo[33J.l3'7]dec-l-ylmethyI)-beiuamide
O


15

Prepared according to the procedure described in Example 6£
MS(APCI+ve) 473/475(M+H)+

WO 01/44170 PCT/SEOO/02505
67
Example 47
2-Chloro-5-[3^ethyIpropylarruno)propyl]-N-(tricyclo[3-3.1.13,7]dec-l-ylmethyl)-benzamide

Prepared according to the procedure described in Example 6f.
MS(APCI-t-ve) 431/433(M+H)+
Example 48
2-Chloro-5-[3-[methyl(l-methyIethyl)amino]propyl)-N-(tricycloij^.i.i jucu-x-ylmethyl)-benzanu'de

WO 01/44170 PCT/SE00/02505
68
Prepared according to the procedure described in Example 6f. MS (APCI +ve) 417/419(M+H)+
5 Example 49
2-Chloro-5-[3-[[3-(dimethyIainino)propyl]methylamino]propyI]-N-(tricyclo [3.3.1.13*T] dec-1-ylmethyl)-benzamide

N —
/
10 .
Prepared according to the procedure described in Example 6f.
MS (APCI+ve) 460/462(M+H)+
15 Example 50
2-CWoro-5-[3-[cycloheiyl(2-hydroxyemyl)ainino]propyl]-N-(tricyclo[33.1.13'7]dec-l-
ylmetliyl)-benzamide

WO 01/44170

PCT/SEOO/02505

69



Prepared according to the procedure described in Example 6f.
5 . MS (APCI +ve) 487/489(M+H)+
Example 51
2-ChLoro-5-[3-(cyclohexylmethylamiiio)propyI]-N-(tricyclo[3J.l.l3,7]dec-l-ylmethyl)-
benzamide
vo
^-/ /=
O

10
15

Prepared according to the procedure described in Example 6f.
MS(APCI+ve) 457/459(M+H)+

WO 01/44170

PCT/SE00/02505

70
Example 52
2-ChIoro-5-[3-(cycIohexyIamino)propyl]-N-(tricyclo[3.3.1.13"7]dec-l-yImethyl)-benzamide



Prepared according to the procedure described in Example 6f.

10

MS (APCI +ve) 443/445(M+H)+
Example 53
2-ChIoro-5-[3-[[l-(hydroxymethyl)-2^-dimethyIpropyI]amino]propyl]-N-
(tricyclo[33.1.13'7]dec-l-yImethyI)-benzamide
O
CI

WO 01/44170 PCT/SEOO/02505
71
Prepared according to the procedure described in Example 6f.
MS(APCI+ve) 46i/463(M+H)+
5 Example 54
2-Chloro-5-[3-(cyclopropyIamino)propyl]-N-(tricyclo[33.1.13,7]dec-l-ylmethyI)-benzamide
\J
NH
io Prepared according to the procedure described in Example 6f.
MS(APCI+ve) 401/403(M+H)*
Example 55 is 2-Chloro-5-[3-[[2-(dimethylammo)ethyI]amino]propyL]-N-(tricyclo[3J.l.l3,7]dec-l-ylmethyl)-benzamide

WO 01/44170

PCT/SE00/02505

72

—N
Prepared according to the procedure described in Example 6f.
5 MS (APCI +ve) 432/434(M+H)+
Example 56
2-ChIoro-5-[3-[(3-hydroxy-2^-dimethyIpropyI)amino]propyl]-N-(tricyclo [3.3.1 .l3,7] dec-l-ylmethyl)-benzamide
10


CI •

Prepared according to the procedure described in Example 6f.

WO 01/44170

PCT/SEOO/02505

73

MS(APCI+ve)447/449(MW
Example 57
2-Chloro-5-[3-[(l,l-dimethylethyI)amino]propyl]-N-(tricyclo[33.1.13,7]dec-l-5 yLmethyl)-ben2amide
H

O

Prepared according to the procedure described in Example 6£.
10 MS(APCI+ve) 417/419(M+H)+
Example 58 2-Chloro-5-[3-[[3-(dimethyIammo)propyl]aimno]propyl]-N-(tricyclo[33.1.1:5-7]dec-l-
ylmethyl)-benzamide
is

WO 01/44170

PCT/SE00/02505

74
*>>~
/
Prepared according to the procedure described in Example 6f.
5 MS (APCI +ve) 446/448(M+H)+
Example 59
2-Chioro-5-[3-(cyclopenrylamiiio)propyl]-N-(itricycIo[3J.l.l3T7]dec-l-yImethyl)-
benzamide
O


10

Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 429/431 (M+H)+

WO 01/44170

PCT/SE00/02505

75
Example 60
Z-Chloro-NKtricycIopJ.l.l^'Jdec-l-ylmethyO-S-IS-fa^^-trimethylpropyl)amino]propyl]-benzamide

Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 445/447(M+H)+
10 Example 61
5-[3-(Butylamino)propyll-2-chloro-N-(tricyclo[33.1.1:3'7] dec-l-ylmethyl)-benzamide
b>k

WO 01/44170 PCT/SE00/02505
76
Prepared according to the procedure described in Example 61
MS(APCI+ve) 417/419(M+H)+
5 Example 62
2-Chloro-5-[3-[[l-(hydroxymethyl)-2-methylpropyl]amino]propyI]-N-(tricycIo[3.3.1.13'7]dec-l-ylmethyI)-benzamide

10
Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 447/449(M+H)+
15 Example 63
^-Chloro-S-p-lCl-methylpropy^aniinojpropyll-NKtricyclopj.l.l^ldec-l-ylmethyl)-benzamlde

WO 01/44170

PCT/SE00/02505

77

Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 417/419(M+H)+
Example 64
2-Chloro-5-[3-[[2-(methylthio)etiiyl]amino]propyl]-N-(tricyclo[33.1.13,7]dec-l-
ylmethyl)-benzamide


b-V


10

Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 435/437(M+H)+

WO 01/44170

PCT/SEOO/02505

78

Example 65
2-ChIoro-5-[3-[(2-hydroxy-14^imetfaylethyI)aminoIpropyl]-N-(tricyclo[3J.l.l3,7]dec-l-ylmethyl)-benzamide
HJ
u
O
CI
Prepared according to the procedure described in Example 6f.
MS (APCI +ve) 433/435(M+H)*

10 Example 66
2-CUoro-5-[3-[(cyclohexylmethyl)amino]propyl]-N-(tricyclo[33.1.13,7]dec-l-
ylmethyl)-benzamide
O
CI
15 Prepared according to the procedure described in Example 6f.

WO 01/44170 PCT/SE00/02505
79

MS (APCI +ve) 457/459(M+H)+ Example 67
5 2-ChIoro-5-[3-(2-propenylamino)propyl]-N-(tricyclo[3J.l.l3'7]dec-l-ylmethyl)-benzamide
0. ... CI
Prepared according to the procedure described in Example 6f. 10 MS (APCI+ve) 401/403 (M+H)+
Example 68 2-Chloro-5-[3-[(2-fluoroethyl)amino]propyl]-N-(tricyclo[33.1.13'7]dec-l-ylinethyl)-
benzamide
15

WO 01/44170

PCT/SE00/02505

80



Prepared according to the procedure described in Example 6f.
5 MS (APCI +ve) 407/409 (M+H)+
Example 69
2-ChIoro-5-[3-[(2-methoxy-l-memylethyI)amino]propylI-N-(tricyclo(3J.l.l3,7]dec-l-
ylmethyl)-benzamide
10


Vv"

Prepared according to the procedure described in Example 6£
MS(APCI+ve) 433/435 (M+H)+

WO 01/44170

PCT/SEOO/02505

81
Example 70
2-Chloro-5-[3-[3-(methylamino)propoxy]propyl]-N-(tricycIo[3J.l.l3-7]dec-l-ylmethyl)benzamide, dihydrochloride salt
H

\^

a) 2-Chloro-5-(3-iodopropyl)-N-(tricyclo[33.1 .l3-7]dec-l-ylmethyl) benzamide
10
2-CWoro-5-(3-hydxoxypropyl)-N-(tricyclo[3.3.1.13-7]dec-l-ylmemyl)-ben2amide(5.9 g, Example 6d), iodine (6.2 g, 24.4 mmol), triphenylphosphine (6.4 g, 24.4 mmol) and imidazole (1.66 g, 24.4 mmol) were stirred in dichloromethane (100ml) at room temperature for 1 h. The reaction was quenched with sat. aq. NajSjOj and the layers were separated. The aqueous phase was extracted with ethyl acetate. The combined organic phases, were dried (NajSOJ, concentrated and purified by column chromatography on silica (eluting with EtOAc : isohexane /l : 3) to afford the subtitled compound as a pale yellow solid (6.8 g) is MS (APCI+ve) 472/474 (M+H)+.
b) 2-CbJoro-5-[3-[3-(methylamino)propoxy]propylJ-N-(tricycIo[3J.l.l3,7]dec-l-ylmethyl)benzamide, dihydrochloride salt
Silver trifluoroacetate (0.7 g, 3.2 mmol) was added to 1,1-dimethylethyl (3-20 hydroxypropyl)methyl caibamic acid (1.8 g, 9.5 mmol) [Synth. Commun. (1995), 25(14), 2135-43] in dichloromethane (20 ml). After lOmin. 2-chloro-5-(3-iodopTopyl)-N-(tricyclo[3.3.1.13J]dec-l-ylmethyl) benzamide (-1.0 g,Example 70a) was added and the mixture was stirred for 24 h. The resulting mixture was washed with water and

WO 01/44170

PCT/SE00/02505

82
concentrated. Treatment with 4M hydrochloric acid in 1,4-dioxane/methanol, concentration and purification by RPHPLC gave the title compound (26 mg) as a white solid.
MS (APCI +ve) 433/435 (M+H)+ 5 *HNMR (DMSO-d6) 8.79-8.35 (1H, m), 8.29 (1H, t, J = 6.2 Hz), 7.38 (1H, d, J = 8.1 Hz), 7.31-7.14 (m, 2H), 3.48-3.31 (4H, m), 2.98-2.81 (4H, m), 2.63 (2H, t, J = 7.6 Hz), 2.50 (3H, s), 1.94 (3H, s), 1.87-1.73 (4H, m), 1.64 (6H, m),.l .52 (6H, m)
Example 71 io 5-[[[(l-Aminocyclopropyl)methyI](2-hydroxyethyl)amino]methyl]-2-chIoro-7V-(tricyclo[3.3.1.13,7]dec-l-yIinethyl)-benzamide




15
20

a) 5-Bromomethyl-2-chloro-benzoic acid
To a stirred solution of 2-chloro-5-methyl-benzoic acid (25g) in chloroform (500ml) at 50°C wasadded N-bromosuccinimide (27.40g). The flask was purged with nitrogen and azobiswobutyronitrile (0. lOg) added in one portion. The solution was heated at reflux for lh. Further azobiswobutyronitrile (0.1 Og) was added and the mixture heated a further 3h. The solution was concentrated in vacuo, redissolved in diethyl ether and filtered to remove insoluble succinimide. The ether solution was washed with 2N aqueos hydrochloric acid solution followed by brine then dried over magnesium sulphate. The solution was concentrated to a volume of 150ml then diluted with isohexane. After further partial

WO 01/44170

PCT/SE00/02505

83
concentration crystallization started. The mixture was allowed to stand in an ice-bath for lh. The resulting crystals were filtered, washed with isohexane and dried in vacuo to give the subtitled compound (17g).
b) S-Bromomethyl-l^hloro^-Ctricydopj.lJSjTldec-l-ylmethyQ-benzamide
To a stirred solution of 5-bromomethyl-2-chloro-benzoic acid (Example 71a, 12.4g) in dichloromethane (250ml) and dimethylformamidej[0.12ml) at 0°C was added oxalyl chloride (8.7ml). The cooling bath was removed and the solution allowed to warm to room temperature. Once gas evolution had ceased the solution was concentrated in vacuo. The residue was redissolved in dichloromethane (300ml), cooled to 0°C and treated with .,-. dzwopropylethylamine (12.4 ml) and adamantylmethylamine (7.54ml). After 15min. at 0°C the solution was poured into diethyl ether (1L) and washed with IN aqueous hydrochloric acid followed by brine. The organics were dried over magnesium sulphate and concentrated in vacuo to give the title compound as a white powder (19g)
MS (APCI+ve) 396/398 (M+H)+
'HNMR (DMSO-dg) 5 8.39 (IH, t); 7.50-7.40 (2H, m); 4.74 (2H, s); 2.92 (2H, d);
2.50 (3H, s); 1.94 (3H, s, br); 1.67 (3H, d); 1.59 (3H, d); 1.52 (6H, s).
c) 2-CWoro-5-[[(2-hydroxyetbyl)amino}methyI]-iV-(tricycIo[33.1.1v]dec-l-ylmethyl)-benzamide
A mixture 5-(bromomemyl)-2-cMoro-N-(2-tricyclo[3.3.1.1J' ]dec-l-ylmethyl)-
benzamide (Example 71b, 0.300 g) and ethanolamine (0.5 ml) in toluene (40 ml) was heated at L00°C for 24h. The mixture was cooled, poured into saturated aqueous sodium hydrogencarbonate solution, extracted into ethyl acetate, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give the subtitled compound as a gum (0.280 g). MS (APCI +ve) MW 377/379 (M+H)+

WO 01/44170

PCT/SE00/02505

84
d) [l-[[[[4-Ch]oro-3-[[(tricyclo[3J.l.l3'7]dec-l-ylmethyI)amino]carbonyIIphenyl]-methyl](2-hydroxyethyl)amino]niethyl]cyciopropyl]-carbamic acid, 1,1-dimethylethyl ester
2-Chloro-5-[[(2-hydroxyethyl)amino]methyl]-//-(tricyclo[3.3.1.137]dec-1 -ylmethyl)-benzamide (0.250 g, Example 71c), (l-formylcyclopropyl)-carbamic acid, 1,1-dimethylethyl ester (0.260 g), sodium triacetoxyborohydride (0.600 g) and dichloromethane (50 ml) were stirred together under nitrogen for 24h. The mixture was poured into saturated aqueous sodium hydrogencarbonate solution, extracted into dichloromethane, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was purified on silica gel (ethyl acetate), to afford the subtitled compound (0.302 g).
MS (APCI +ve) MW 546/548 (M+H)+
e) 5-[[[(l-Anu^ocyclopropyl)methyI](2-hydroxyethyl)amino]methyl]-2-chIoro-A':-(tricyclo [3 3.1.I3,7] dec-l-ylmethyl)-benzamide
[l-[[[[4-Chloro-3-[[(tricyclo[33.1.13-7]dec-l-ylmemyl)ainmo]caibonyl]phenyl]-memyl](2-hydroxyethyl)amiiio]methyl]cyclopropyl]-carbamic acid, 1,1-dimethylethyl ester (Example 71d, 0.302 g) was dissolved in methanol (10 ml) and 4N HC1 in dioxane (10 ml) was added. The mixture was stirred for 14h at room temperature, then poured into 25% aqueous ammonia solution and concentrated under reduced pressure to give the free base. This was purified by column chromatography over silica (eluting with 19:1:0.1 dichloromethane/methanol/ ammonia) to afford the title compound as an oil (0.230 g).
MS (APCI +ve) MW 446/448 (M+H)+
lH NMR (CDC13) 5 7.69 (1H, s); 7.37 (2H, m); 6.38 (1H, t, br); 3.73 (2H, s); 3.64 (2H, t);
3.18 (2H, d); 2.74 (2H, t); 2.49 (2H, s); 2.21 (3H, s, br); 2.01 (3H, s, br); 1.75-1.64 (6H, . m); 1.59 (6H, s, br); 0.59 (2H, t); 0.40 (2H, t).

WO 01/44170

PCT/SE00/02505

85
Example 72
5-[[(2-Hydroxyethyl)[2-(inetfaylaiiuiio)ethyI]aniino]methyl]-2-methyI-iV-(tricyclo[3J.l.l3'7]dec-l-ylmethyl)-ben2amide

a) [2-[(2-Hydroxyethyl)[[4-methyl-3-[[(tricyclo[3J.l.l3J]dec-l-ylmethyI)amino]carbonyl]phenyl]methyl]amino]ethyI]methyl-carbamic acid, 1,1-dimethylethyl ester
2-Chloro-5-[[(2-hydroxyethyl)amino]methyl]-^-(tricyclo[3.3.1.13-7]dec-1 -ylmethyl)-benzamide (0.30 g, Example 71c), methyl(2-oxoethyl)-carbamic acid, 1,1-dimethylethyl ester (0.276 g), sodium triacetoxyborohydride (0.720 g) and dichloromethane (50 ml) were stirred together under nitrogen for 24h. The mixture was poured into saturated aqueous sodium hydrogencarbonate solution, extracted into dichloromethane, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude material was purified on silica (eluting with 19:1 dichloromethane/methanol) to afford the subtitled compound (0.285 g).
MS (APCI +ve) MW 534/536 (M+H)+
b) 5-[[(2-HydroxyethyO(2^methyIamino)eaiyI]amino]methyll-2-methyl-Ar-(tricycloP3.1.13*7]dec-l-yImethyI)-ben2amide

WO 01/44170

PCT/SE00/02505

86
[2-f(2-HydroxyethyI)[[4-methyl-3-[[(tricyclo[3.3.1. l3-7]dec-1-
ylme1±iyl)aniino]carboriyl]pheriyl]rnetliyl]ainino]ethyl]rnethyl-carbainic acid, 1,1-
dimethylethyl ester (Example 72a, 0.285 g) was dissolved in methanol (10 ml), 4N HCl in dioxane (10 ml) was added and the mixture stirred for 14h at room temperature. The 5 solution was poured into 25% aqueous ammonia solution and concentrated under reduced pressure to give the free base. This was purified by chromatography over silica gel (eluting with 8:2:0.2 / dichloromethane.-methanol: ammonia) to afford the tide compound as an oil (0.167 g).
10 MS (APCI +ve) MW 434/436 (M+H)+
JH NMR (CDC13) 5 7.65 (1H, s); 7.35 (2H, s); 6.41 (1H, t, br); 3.67 (2H, s); 3.57 (2H, t);
3.17 (2H, d); 2.68-2.61 (6H, m); 2.38 (3H, s); 2.01 (3H, s, br); 1.76-1.63 (6H, m); 1.60 (6H, s, br).
15 Example 73
2-Chloro-5-[3-[[2-(l-methyl-l/T-imidazoW-yI)ethyl]aniino]propyl]-A^ (tricyclo[3-3.1.13,7]dec-l-ylmethyI)benzainide

20 Synthesized from 2-chloro-5-[3-[(methylsulfonyl)oxy]propyl]-N-
(Mcyclo[3.3.1.13J]dec-l-ylmemyl)-beri2amide (Example 6e, 0.5g) and 3-methylhistamirje (0.22g) according to the procedure described in Example 6f to afford the title compound (0.060g).

WO 01/44170

PCT/SE00/02505

87
MS (AFCl +ve) 469/471 (MtH)+
'H NMR (DMSO-d6) 5 9.45-9.30 (2H, m); 9.02 (IH, s); 8.32 (IH, t); 7.55 (IH, s); 7.41 (IH, d); 7.28 (IH, d); 7.26 (IH, d); 3.82 (3H, s); 3.30-3.20 (2H, m); 3.15 (2H, t); 2.95-2.85 (4H, m); 2.70 (2H, t); 2.02-1.93 (5H, m); 1.63 (6H, q); 1.52 (6H, s).
Example 74
2-Chloro-5-[3-[[2-(l^-imidazoI-4-yI)ethyIJaminoIpropyl]-A^-(tricyclo[3J.l.l3,7]dec-l-
ylmethyl)benzamide



10 Synthesized from 2-chloro-5-[3-[(methylsulfonyl)oxy]propyI]-N-(tricyclo[3.3.1. l3,7]dec-l-ylmethyl)-benzamide (Example 6e, lmg) and histamine according to the procedure described in Example 6f to afford the title compound.

15

MS (APCI +ve) 455/457 (M+H)+
Example 75 2-CWoro-5-[3-[[3-(l^-iimdazoI-l-yI)propyI]aminolpropyI]-iV-(tricycIo[3J.l.l3-7]dec-l-
ylmethyl)benzamide

WO 01/44170 PCT/SE00/02505
88


J§

Synthesized from 2-chloro-5-[3-[(methylsulfonyl)oxy]propyl]-N-(tricyclo[3.3.1.13'7]dec-l-ylmethyl)-benzamide (Example 6e, lmg) and l-(3-5 aminopropyl)imidazole according to the procedure described in Example 6f to afford the title compound.
MS (APCI +ve) 469/471 (M+H)+
10 Example 76
Z-CUoro-S-P-lCS-hydroxypropylJaminolpropylJ-A^-^cyclopj.l.l^jdec-l-ylmethyl)-benzamide, hydrochloride salt




Sodium triacetoxyborohydride (4.1 Og) was added to a solution of 2-chloro-5-(3-
15 oxopropyl)-N-(tricyclo[3.3.1. l3,7]dec-l-ylme%I)-beuzamide (3.46g, Example 14b) and 3-aminopropanol (1.73ml) in dichloromethane (200ml). After 24h die crude reaction mixture was purified by flash chromatography (eluting with 5-20% methanol /

WO 01/44170

PCT/SE00/02505

89
dichloromethane + 1% ammonia) and the hydrochloride salt precipitated from ether/methanol 19:1, to afford the title compound as.a white solid (1.60g).
MS (APCI+ve) 419/421 (M+H)+
5 lH NMR (DMSO-d6) 5 8.67 (2H, s); 8.31 (1H, t); 7.41(1H, d); 7.30-7.25 (2H, m); 4.7.4
(1H, t); 3.47 (2H, q); 2.95-2.85 (6H, m); 2.67 (2H, t); 2.00-1.84 (5H, m); 1.76 (2H, quin);
1.63 (6H,q); 1.52 (6H,s). . .
Pharmacological Analysis
io Certain compounds such as benzoylbenzoyl adenosine triphosphate (bbATP) are
known to be agonists of the P2X7 receptor, effecting the formation of pores in the plasma membrane (Drug Development Research (1996), 37(3), p. 126). Consequently, when the receptor is activated using bbATP in the presence of ethidium bromide (a fluorescent DNA probe), an increase in the fluorescence of intracellular DNA-bound ethidium bromide is
15 observed. The increase in fluorescence can be used as a measure of P2X7 receptor activation and therefore to quantify the effect of a compound on the P2X7 receptor.
In this manner, each of the title compounds of the Examples was tested for antagonist activity at the P2X7 receptor. Thus, the test was performed in 96-well fiat bottomed
20 microtitre plates, the wells being filled with 250 p.1 of test solution comprising 200 ul of a suspension of THP-l cells (2.5 x 10 cells/ml) containing 10 M ethidium bromide, 25 \i\ of a high potassium buffer solution containing 10" M bbATP, and 25 p.1 of the high potassium buffer solution containing 3x10" M test compound. The plate was covered with a plastics sheet and incubated at 37 °C for one hour.. The plate was men read in a
25 Perkin-Elmer fluorescent plate reader, excitation 520 nm, emission 595 nm, slit widths: Ex 15 nm, Em 20 nm. For the purposes of comparison, bbATP (a P2X7 receptor agonist) and pyridoxal 5-phosphate (a P2X7 receptor antagonist) were used separately in the test as controls. From the readings obtained, a pIC5o figure was calculated for each test compound, this figure being the negative logarithm of the concentration of test compound

WO 01/44170 PCT/SEOO/02505
90
necessary to reduce the bbATP agonist activity by 50%. Each of the compounds of the
Examples demonstrated antagonist activity, having a pIC5Q figure > 5.0.

VA£ CJJMVU-
1. A pharmaceutical composition comprising from 0.05 to 99 %w of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in association with from 1 to 99.95 %w of a pharmaceutically acceptable adjuvant, diluent or carrier, wherein formula (I) is:



wherein D represents CH2 or CH2CH2;
E represents C(0)NH or NHC(O);
12 R andR each independently represent hydrogen, halogen, amino, nitro, Cj-Csalkyl
1 2
or trifluororxjethyl, but R and R may not both simultaneously represent hydrogen;
3 R represents a group of formula



(n);

4 R represents a C1-C6 alkyl group;
13 X represents an oxygen or sulphur atom or a group NR , SO or SO2;
R represents C^-Cg alkyl or C2-C6 alkenyl, each of which may be optionally substituted
by at least one substituent selected from halogen, hydroxyl, (mO-Ci-Cg-alkylamino,
-Y-R6, and

a 5- or 6-mcmbered heteroaromatic ring comprising from 1 to 4 beteroatoms independently selected from nitrogen, oxygen and sulphur which heteroaromatic ring may itself be optionally substituted by at least one substituent selected from halogen, hydroxyl and
Ci-C6 alkyl;
Y represents an oxygen or sulphur atom or a group NH, SO or SO2;
R represents a group -R Z where R represents a C2-Cg alkyl group and Z represents an
-OH, -C02H, -NR8R9, -C(O)NRl0RU or -N(R12)C(0)-Ci-C6 alM group, and,
in the case where Y represents an oxygen or sulphur atom or a group NH, R additionally
represents hydrogen, Cj-Ce alkyl, C1-C6 alkylcarbonyl, Ci-Cgalkoxycarbonyl,
-C(0)NR14R15, -CH2OC(0)R16, -CH2OC(0)OR17 or -C(0)OCH2OR18;
R , R , R , R and R each independently represent a hydrogen atom or a C1-Q5 alkyl
group;
13 13
R represents hydrogen, C3-Cg cycloalkyl, C3-C8 cycloalkylmethyl, or R represents a
Cj-Cg alkyj group optionally substituted by at least one substituent selected from hydroxyl
and Cj-Cg alkoxy; and
R ,R ,R ,R andR each independently represent a Ci-Cg alkyl group;
with the proviso that when E is C(0)NH, X is O, NH or N(Ci-C6 alkyl), then R5 is other
than an unsubstituted C\-Cs alkyl group.
2. A pharmaceutical composition according to claim 1, wherein in formula (I) D represents CH2.
3. A pharmaceutical composition according to claim 1 or claim 2, wherein in formula (I) E represents NHC(O).

I 2
formula (I) R and R each independently represent a hydrogen, chlorine 01 bromine atom.
4. A pharmaceutical composition according to any one of claims 1 to 3, wherein in
t 2
formula (I) R and R each independently represent a hydrc
or an amino, nitro, Ci-Ci alkyl or trifluorometbyl group.

5. A pharmaceutical composition according to any one of the preceding claims, wherein
13 in formula (I) X represents an oxygen atom or a group NR .
13
6. A pharmaceutical composition according to claim 5, wherein in formula (I) R
represents hydrogen, -(CEfchOH, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, cyclopropyl, cyclopentyl, cyclohexyl or cyclohexylmethyl.
7. A pharmaceutical composition according to any one of the preceding claims, wherein in formula (I) R represents a Cj-C6 alkyl group substituted by a single substituent -Y-R .
8. A pharmaceutical composition according to any one of the preceding claims, wherein in formula (I) Y represents an oxygen or sulphur atom or a group NH.
9. A pharmaceutical composition according to claim 8, wherein in formula (I) R represents-(CH2)20H, -(CH^OH, hydrogen, methyl, isopropyl, methylcarbonyl or t-butylcarbonyl.
10. A pharmaceutical composition according to claim 1, wherein the compound of formula (I) is selected from:
2-ChIoro-5-[[2-(2-hydroxy-ethyIamino)-ethylamino]-methyl]-iV:-(tricycJ o[3.3.1.13,7]dec-1 -ylmethyl)-benzamide dihydrochloride,
2-Chloro-5-[[2 2-Chloro-5-[(3-hydroxy-2,2-dimemylprci>ylamino)methyl]-iV-(tricycIop.3.1.13'7Jdec-l-ylmethyl)-benzamide,
2-Chloro-5-[(5-hydroxypentylamino)methyl]-Ar-(tricyclo[3.3.1. l3,7]dec-1 -ylmerhyl)-
beraamide,
2-Chloro-5-[[2-[(2-hydroxyethyltJuo)e^ l-ylmethyl)-benzamide,

2-ChIoro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1. l3,7]dec-l-
ylmethyl)-benzaraide? acetate salt,
2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1. l3,7Jdec-l-ylmethyl)-benzamide, hydrochloride salt,
2-Chloro-5-[3^mcthyIainino)propyl]-iV-(tricyclo[3.3.1.I3'7]dec-l-ylmcthyl)-benzamide, acetate salt,
2-ChIoro-5-[3 5-[3-[(2-Amino-2-methyIpropy])amino]propyl3-2-ch]oro-JV-(tricyclof3.3.lJ3,7]dec-l-
ylmethyl)-benzamide, dihyrdrochloride salt,
2-Chloro-5-[3-[(4-hydroxybutyl)aniiiio]propyl]-//-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-benzamide,
2-Chloro-5-[34(2-hydroxy-2-methylpropyl)amino]propyl]-A'r-(tricyclo[3.3.1.13'7]dec-
l-ylmethyl)-benzamide, acetate salt,
2-Chloro-5-[3^[2-(methylamino)ethyl]amino]propyl]-N-(tricycIo[3.3.1.13'7Jdec-l-
ylmethyl)-benzamide, dihydrochloride salt,
(S)-2-Chloro-5-[3-[(2-hydroxypropyl)aminoJpropyI]-N-(tricycJo[3.3.1.1J']dec-l-ylmethyl)-benzamide, hydrochloride salt,
(R)-2-Chloro-5-[3-[(2-hydroxyrm)pyl)ajriino]propyl]-N-(tricyclo[3.3.1.13JJdec-l-ylmethyl)-benzamide, hydrochloride salt,
(R)-2-thloro-5-[3-[(2-hydroxy-l-methyl«hyl)amino]propyl]-N-(tricyclo[3.3.1.13'7]dec-l-ylmethyI)-benzamide, hydrochloride salt,
2-Chloro-5-[3-[[2-hydroxy-l-(hydroxymethyl)-l-methyIcthyl]amino]propyl]-N-
(tricyclo(3.3.1. l3'7]dec-l-ylmethyl)-benzamide,
S-[3-[[2-(Acetylaniino)ethyl]arnino]propyl]-2-chIoro-N-(tricyclo[3.3-l.l3'7]dec-l-ylmethyO-benzamide, hydrochloride salt,
2-Chloro-5-[3-[[2Ktfethylamino)ethyI]aim^
ylmethyD-benzamide, dihydrochloride salt,
2-ChIoro-5-[3-[(3-metooxypi^yl)a^^ ylmcthyl)-bcnzamide, hydrochloride salt,

2-Chloro-5-[3-[(3-hydroxy-3-methylbutyl)amino]propy]]-N-(iricycIof3-3.1.1 ' Jdec-
l-ylmethyD-benzamide, hydrochloride salt,
2-Chloro-5-[3'[(2-methoxyethy))amino]propyI]-N-(tricycIo[3.3.I.l3-7]dec-l-
ylmethyl)-benzamide, hydrochloride salt,
2-Chloro-S-[[3-(methylamino)propoxy]methyl]-N-(tricycIo[3.3.1.13,7]dec-1 -
ylmethyl) benzamide,
2-ChIoro'5-[C2-[(2-hydroxycthyl)aniino)ethoxylmethyl]-N-(tricyclo[3.3.1.13'7]dec-l-
ylracthyl)-benzamidc, acetic acid salt,
2-ChIoro-5-[[2-[(3-hydroxypropyl)amino]ethoxy]methy]]-N-(tricyclo[3.3.1. l3J]dec-
l-ylmethyl)-benz&roide, acetic acid salt,
2-Chloro-5-[[[3-[(l-mcthy]ethyI)amino]propyl]araino]methyl]-N-
(tricyclo[3.3.1. l3,7]dec-l-ylmethyl)-benzamide,
5-[[(3-Aminopropyl)amino]methyl]-2-chloro-N-(tricycIo[3.3.1. l3,7]dec-X-ylmethyJ)-benzamide,
2-Chloro-5-[[[2-[(l-methylethy])amino]ethyI]aminoJmethyl]-N-(tricyclo[3.3.1.13,7]dec-l-ylmethyI)-benzamide,
3-[[3-[4-Chloro-3-[[(tricydo[3.3.1. l^'ldec-l-ylmethyDamino]-
carbonyl]phenyl]propyl]amino]propanoic acid, 2,2-dimethylpropyI ester, trifluoroacetic
acid salt,
2-Chloro-5-[3-[(2-hydroxycthyI)pentylamino]propyl)-N-(tricyclo[3.3.1.13J]dec-l-
ylmcthyl)-benzamide,
2-Chloro-5-[3-(methyl-2-propenylamino)propyl}-N-(tricyclo[3.3.1.1 • Jdec-1-
ylniethyl)-benza7nide,
2-Chloro-5-[3-[[2-(dimethylamino)ethyl]methylaraino]propyl)-N-(tricyclo[3.3.1.13'7]dec-l-ylmethyl)-benzamide,
5-[3-(Butylethylamino)propyl]-2-chloro-N-(tricyclo[3.3.1.13,7]dec-l-y]methyl)-
benzairiidc,
2-Chiorc-5-[3-(methylpeittylam^^ benzamide,

2-Chloro-543^[2-(diethylamino)ethyl]ethylaminoJpropyI]-N-(tricycIo[3.3.1.13,7]dec-
1 -ylmethyJ)-benzamide,
2-Chloro-5-[3-[(2-hydroxyethyI)niethyIamino]propyl]-N-(tricyclo[3.3.1.13-7]dec-l-
ylmethyl)-benzaroide,
2-Chloro-5-[3-(dipropyIammo)propyl]-N-(tricyclo[3 3.1.13,,]dec-l-ylmethyl)-benzamide,
2-Chloro^5-r3-[(2-hydroxyethyl)(l-methylethy])amino]propyl]-N-(tricyc]o[3.3.1.13,7]dec-l-y]methyl)-benzamide,
5-[3-[Butyl(2-hydroxyethy])amino]propyl]-2-chloro-N-(tricyclo[3.3.1. l3,7]dec-l-ylmethyl)-benzamide,
2-Chioro-5-[3-(dicthy]amino)propyl]-N-(tricyclo[3.3.1.13'7]dec-l-ylmethyI)-
benzamide,
2-Chloro-5-[3-(dimcthylamino)propyl]-N-(tricyclo[3.3.1.13'7Jdec-l-yImethyI)-benzamide,
5-[3-(Buty]methyIamino)propyl]-2-cbIoro-N-(tricycIo[3.3.1.13-7]dcc-l-yImcthyl)-
benzamide,
2-ChIoro-5-[3-((2-hydroxycthyl)propyJamino]prOpyl]-N-(tricycloL3.3.1.13r7]dec-l-ylmethyl)-benzamidc,
2-ChIoro-5-[3-[ethyl(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1. l3,7]dec-l -
ylmethyl)-benzamide,
2-Chloro-5-[3-(dibutylan)ino)propyl]-N-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)-
benzamide,
2-Chloro-5-[3-(cthy]propyIamino)propyl]-N-(tricyclo[3.3.1.13'7)dec-l-ylmethyl)-
benzamide,
2-Ch]oro-S-[3-[methyl(l-methylcthyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dcc-l-
ylmethy])-benzamide,
2-ChIoro-5-[3-[[3^diraethylainino)propyl]methyiamino]propyJ]-N-
(tricycIo[3.3.Ll3-7Jdec-l-ylmcthyl>benzamidcT
2-Chloro-5-[3-[cyclohcxyl(2-hydroxy6thyl)aminoJpropyl]-NKtricyclo[3.3.1.13,7]dec-l-ylmcthyl)-benzainide,

2-Chloro-5-[3-(cyclohexylmethylamino)propy]J-N-(tricyclo[3.3.I.r]dec-l-
ylmethyl)-benzami de,
2-Chloro-5-[3-[[l-(hydroxymethyI)-2,2-diinethylpropy)]amino]propyl]-N-
(tricyclo[3.3.1.13,7]dec4-ylmethyl>benzamide,
2-ChIoro-5-[3-f[2-'(dJTnethylamino)ethyl]aniino]propyl]-N-(tricyc]o[3.3.1.1 ' ]dec-l-
ylmethyO-benzamide,
2-Chloro-5-[3-[(3-hydroxy-2,2-diroethylpropy])amino)propy]]-N-
(tricyclo[3.3.1.13 7]dec-l-ylmethyl)-benzamide,
2-Chloro-5-[3-[(l,l-di7Tiethy]ethyl)airano]propy1]-N-(tricyc]o[33.1.13'7]dec-l-
yjmethyl)-benzamide,
2-Chloro-5-[3-[(3-(dJmethylamino)propyl]amino]propy]]-N-(tiicyclo[3.3.1.1 ' ]dec-
l-ylmethylj-benzamide,
2-Chloro-N-(tricyclo[3.3.1 .l3'7]dec-l-ylmethyl)-5-[3-[( 1,2,2-trimethylpropy])amino)propyl]-benzamide,
5-[3-(Butylamino)propyl]-2-chloro-N-(tricyclo[3.3.1.13'7]dec-1 -ylmethyl)-
benzamide,
2-ChJoro-5-[3-[[l-(hydroxymethyI)-2-mcthy]propyl)amino]propyf[^N:
(tricyclo[3.3.1. l3'7]dcc-l-ylmethyl)-bcnzamide,
2-Chloro-5-[3-[( l-mcthylpropyl)ainino]propyl]-N-(tricyclo[3.3-1. l3'7]dec-l -
ylmethyl)-bcnzamide,
2-Chloro-5-[3-[[2-(mcthylthio)ethyI]amino]propyl]-N-(tricyclo[3.3.1.1 ' ]dec-l-
ylmethyl)-benzamide,
2-Ch5oro-5-[3-[(2-hydroxy-l,l-dimethylcthyl)amino]propyl]-N-
(tricyclo[3.3.1. l3,7]dec-l -ylmethyl)-benzaraide,
2-Chloro-5-[3-(2-propenylamino)propyl]-N-(tricyclo[3.3.Ll3-7]dec-l-ylraethyl)-
benzamide,
2-ChIoro-5-[3-[(2-fluoroethyJ)amino]propyI]-N-(tricycIo[3.3.1.13'7]dcc-I-y]racthy])-
benzamidc,
2^hiOTO-5-[3-[(2-methoxy-l-racthylethyl)amino]propyl]-N-(tricyc]o[3.3.11 • ]dcc-
l-ylmcthyl)-benzamidc,

2-Ch]oro-5-[3-[3-(methylamino)propoxy]propyI]-N-(tricvclo[3.3.1.13'7]dec-l-
ylmethyl)benzamide, dihydrochloride salt,
54[[(l-Arainocyclopropyl)methyl](2-hydroxyeihyl)amino]methyl)-2-chloro-N-
(tricyclo[3.3.1. l3,7]dec- I-ylmethyl)-benzamide,
5-[[(2-Hydroxyethyl)[2-(mcthylamino)cthyl]amino]methyl]-2-methyl-N-
(tricyclo[3.3.1.13'7]dcc- l-ylmethyl)-benzamide,
2-Ch]oro-5-p-[[2-(l-methyl-lH-imidazol-4-yJ)ethyl)amino]propyl)-N-
(tricyclo[3 -3.1. l3,7]dec-1 -ylmethyl)benzamide,
2-Ch]oro-5-[3-[[2-(lH-imidazol-4-y])ethyl]amino]propyl]-N-(tricyclo[3.3.1.l',7ldec-
l-ylmethyl)benzamide, and
2-Chloro-5-[3-[[3'(lH-imidazol-l-yl)propyl]amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-l-ylmethyl)benzamide or a pharmaceutically acceptable salt or solvate thereof.
11. A process for the preparation of a pharmaceurical compositjon as claimed in any one of claims I to 10 which comprises mixing a compound of formula (I), or a
pharinaceutically acceptable salt or solvate thereof, as defined in any one of claims l to iu, with a pharmaceutically acceptable adjuvant, diluent or carrier.


Jl *'
(JAMANTA PAL)
OF REMFRY & SAGAR
ATTORNEY FOR THE/APPLICANTS
Dated this 9th day of February, 2006.

Documents:

160-MUMNP-2006-ABSTRACT 4-7-2008.pdf

160-mumnp-2006-abstract(04-07-2008).pdf

160-MUMNP-2006-CLAIMS 4-7-2008.pdf

160-mumnp-2006-claims(granted)(04-07-2008).pdf

160-mumnp-2006-claims.pdf

160-mumnp-2006-correspondance-received-ver-090206.pdf

160-mumnp-2006-correspondance-received-ver-100406.pdf

160-MUMNP-2006-CORRESPONDENCE 4-7-2008.pdf

160-mumnp-2006-correspondence(04-07-2008).pdf

160-mumnp-2006-correspondence(ipo)-(24-12-2008).pdf

160-mumnp-2006-description (complete).pdf

160-MUMNP-2006-DESCRIPTION(COMPLETE) 4-7-2008.pdf

160-mumnp-2006-form 13(31-07-2007).pdf

160-mumnp-2006-form 18(25-07-2006).pdf

160-MUMNP-2006-FORM 1A 4-7-2008.pdf

160-mumnp-2006-form 1a(04-07-2008).pdf

160-mumnp-2006-form 1a(10-02-2006).pdf

160-mumnp-2006-form 1a(30-07-2007).pdf

160-mumnp-2006-form 2(granted)-(04-07-2008).pdf

160-MUMNP-2006-FORM 2(TITLE PAGE) 4-7-2008.pdf

160-MUMNP-2006-FORM 3 4-7-2008.pdf

160-mumnp-2006-form 3(04-07-2008).pdf

160-mumnp-2006-form 3(10-02-2006).pdf

160-MUMNP-2006-FORM 3(2) 10-2-2006.pdf

160-mumnp-2006-form 5(09-02-2006).pdf

160-mumnp-2006-form-1.pdf

160-mumnp-2006-form-2.doc

160-mumnp-2006-form-2.pdf

160-mumnp-2006-form-26.pdf

160-mumnp-2006-form-3.pdf

160-mumnp-2006-form-5.pdf

160-mumnp-2006-form-pct-ib-304.pdf

160-mumnp-2006-form-pct-ipea-409.pdf

160-MUMNP-2006-OTHER DOCUMENT 10-2-2006.pdf

160-mumnp-2006-pct-search report.pdf

160-MUMNP-2006-PETITION UNDER RULE 137 4-7-2008.pdf

160-mumnp-2006-petition under rule 137(04-07-2008).pdf

160-MUMNP-2006-PETITION UNDER RULE 138 4-7-2008.pdf

160-mumnp-2006-petition under rule 138(04-07-2008).pdf

160-MUMNP-2006-POWER OF ATTORNEY 4-7-2008.pdf

160-mumnp-2006-power of authority(04-07-2008).pdf

160-mumnp-2006-power of authority(24-03-2006).pdf

abstract-1.jpg


« Previous Patent
Next Patent »
Patent Number 227119
Indian Patent Application Number 160/MUMNP/2006
PG Journal Number 10/2009
Publication Date 06-Mar-2009
Grant Date 02-Jan-2009
Date of Filing 10-Feb-2006
Name of Patentee ASTRAZENECA AB
Applicant Address S-151 85 Sodertalje Sweden
Inventors:
# Inventor's Name Inventor's Address
1 LILIAN ALCARAZ, MOYA CAFFREY, MARK FURBER, TIMOTHY LUKER Astrazenece R & D Charnwood, Bakewell Road, Loughborough LE 11 5RH, Grear Britain,
2 MICHAEL MORTIMORE Vertex Pharmacuticals, Ltd. 88, Milton Park Abingdon, Oxfordshire Ox14 4RY, Great Britain
3 AUSTEN PIMM, PHILLIP THORNE Astrazeneca R & D Charnwood, Backewell Road, Loughborough LE11 5RH, Great Britain
4 PAUL WILLIS Astrazeneca R & D Charnwood, Backewell Road, Loughborough LE11 5RH, Great Britain
PCT International Classification Number C07C235/46
PCT International Application Number PCT/SE00/02505
PCT International Filing date 2000-12-12
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 0015744.6 2000-06-27 Sweden
2 9904651-8 1999-12-17 Sweden
3 0017942.4 2000-07-22 Sweden